Lamina Propria and Olfactory Bulb Ensheathing Cells Exhibit Differential Integration and Migration and Promote Differential Axon Sprouting in the Lesioned Spinal Cord Miranda W. Richter ,1 Patrick A. Fletcher ,1 Jie Liu ,2 Wolfram Tetzlaff ,2 and A. Jane Roskams1 1Department of Zoology and 2International Collaboration on Repair Discoveries , University of British Columbia , Vancouver , British Columbia , Canada V5Z 4H4 Olfactory bulb-derived -LRB- central -RRB- ensheathing cell -LRB- OB OEC -RRB- transplants	1
Lamina Propria and Olfactory Bulb Ensheathing Cells Exhibit Differential Integration and Migration	1
Lamina Propria and Olfactory Bulb Ensheathing Cells Exhibit	1
Lamina Propria	1
Olfactory Bulb Ensheathing Cells Exhibit	20
Differential Integration and Migration	61
Promote Differential Axon Sprouting in the Lesioned Spinal Cord Miranda W. Richter ,1 Patrick A. Fletcher ,1 Jie Liu ,2 Wolfram Tetzlaff ,2 and A. Jane Roskams1 1Department of Zoology and 2International Collaboration on Repair Discoveries , University of British Columbia , Vancouver , British Columbia , Canada V5Z 4H4 Olfactory bulb-derived -LRB- central -RRB- ensheathing cell -LRB- OB OEC -RRB- transplants	104
Differential Axon	112
the Lesioned Spinal Cord Miranda W. Richter ,1 Patrick A. Fletcher	143
,1 Jie Liu ,2 Wolfram Tetzlaff ,2 and A. Jane Roskams1 1Department of Zoology and 2International Collaboration	209
,1 Jie Liu ,2 Wolfram Tetzlaff ,2 and A. Jane Roskams1 1Department	209
Zoology and 2International Collaboration	277
Repair Discoveries , University of British Columbia , Vancouver , British Columbia , Canada V5Z 4H4 Olfactory bulb-derived -LRB- central -RRB- ensheathing cell -LRB- OB OEC -RRB- transplants	321
Repair Discoveries	321
University of British Columbia , Vancouver , British Columbia	341
University	341
British Columbia , Vancouver , British Columbia	355
Canada V5Z 4H4 Olfactory bulb-derived -LRB- central -RRB- ensheathing cell -LRB- OB OEC -RRB- transplants	402
Canada V5Z 4H4	402
Olfactory bulb-derived -LRB- central -RRB- ensheathing cell -LRB- OB OEC -RRB- transplants	418
OB OEC	469
significant promise in rat models of spinal cord injury	500
significant promise	500
rat models of spinal cord injury	523
rat models	523
spinal cord injury	537
the use of lamina propria-derived -LRB- peripheral -RRB- olfactory ensheathing cells -LRB- LP OECs -RRB-	567
the use	567
lamina propria-derived -LRB- peripheral -RRB- olfactory ensheathing cells -LRB- LP OECs -RRB-	578
lamina propria-derived -LRB- peripheral -RRB- olfactory ensheathing cells	578
lamina	578
peripheral	602
LP OECs	643
both experimental and clinical trials	655
experimental	660
clinical trials	677
a common embryonic precursor	716
both sources of OECs	746
sources of OECs	751
sources	751
OECs	762
different nervous system compartments	777
their ability to promote regeneration and efficacy after transplantation	832
regeneration and efficacy	857
transplantation	889
both their source and mode of transplantation	929
their source	934
mode of transplantation	951
mode	951
transplantation	959
we	982
green fluorescent protein-expressing LP and OB OECs	999
green fluorescent protein-expressing LP	999
OB OECs	1043
their biological differences	1060
them	1116
rostral and caudal	1153
a dorsolateral funiculus crush	1175
LP and OB OECs	1207
multiple morphological and antigenic similarities	1230
transplantation	1301
they	1318
lesion and cavity formation	1338
angiogenesis , endogenous Schwann cell infiltration , and axonal sprouting	1378
angiogenesis	1378
endogenous Schwann cell infiltration	1392
axonal sprouting	1434
axonal	1434
an increased mitotic rate and migratory ability of LP OECs	1461
an increased mitotic rate	1461
migratory ability of LP OECs	1491
migratory ability	1491
LP OECs	1512
their superior ability	1554
the spinal cord	1595
cavity formation and lesion size	1619
cavity formation	1619
lesion size	1640
outgrowth of axonal subpopulations compared with OB OECs	1682
outgrowth	1682
axonal subpopulations compared with OB OECs	1695
axonal subpopulations	1695
OB OECs	1731
An undesired behavior -LRB- autotomy -RRB-	1740
An undesired behavior	1740
autotomy	1763
LP OEC	1808
OB OEC , transplantation	1821
OB OEC	1821
transplantation	1829
These results	1846
LP and OB OECs	1873
intrinsic biological differences that , after transplantation into the lesioned CNS , result in differences in postlesion spinal cord neuropathology and anatomical and behavioral regeneration outcomes that also vary depending on direct versus rostrocaudal transplantation	1896
intrinsic biological differences	1896
transplantation into the lesioned CNS	1941
transplantation	1941
the lesioned CNS	1962
differences in postlesion spinal cord neuropathology and anatomical and behavioral regeneration outcomes that also vary depending on direct versus rostrocaudal transplantation	1990
differences in postlesion spinal cord neuropathology	1990
differences	1990
postlesion spinal cord neuropathology	2005
anatomical and behavioral regeneration outcomes that also vary depending on direct versus rostrocaudal transplantation	2047
anatomical and behavioral regeneration outcomes	2047
direct versus rostrocaudal transplantation	2123
direct	2123
rostrocaudal transplantation	2137
Introduction The abortive regeneration of CNS neurons	2168
Introduction The abortive regeneration	2168
Introduction	2168
The abortive regeneration	2181
CNS neurons	2210
stark contrast	2228
the renewal capacity of the olfactory system -LRB- Graziadei et al. , 1978 , 1979 -RRB-	2246
the renewal capacity	2246
the olfactory system -LRB- Graziadei et al. , 1978 , 1979 -RRB-	2270
the olfactory system	2270
Graziadei	2292
et al. , 1978 , 1979	2302
et al.	2302
1978	2310
1979	2316
Reconstitution of the olfactory neuraxis	2323
Reconstitution	2323
the olfactory neuraxis	2341
central axotomy -LRB- Zigova et al. , 1992 -RRB-	2385
central axotomy	2385
Zigova	2402
et al. , 1992	2409
et al.	2409
1992	2417
This axonal growth within the CNS	2424
This axonal growth	2424
the CNS	2450
olfactory ensheathing cells -LRB- OECs -RRB- , resident in the peripheral and central olfactory neuraxis -LRB- Doucette , 1990 -RRB-	2491
olfactory ensheathing cells -LRB- OECs -RRB-	2491
olfactory ensheathing cells	2491
OECs	2520
resident in the peripheral and central olfactory neuraxis -LRB- Doucette , 1990 -RRB-	2527
resident	2527
the peripheral and central olfactory neuraxis -LRB- Doucette , 1990 -RRB-	2539
the peripheral and central olfactory neuraxis	2539
Doucette , 1990	2586
Doucette	2586
1990	2596
this reason	2607
the therapeutic potential of olfactory bulb-derived -LRB- OB -RRB- OECs to promote recovery from CNS lesions to descending and ascending spinal tracts -LRB- Li et al. , 1998 ; Ramon-Cueto et al. , 2000 ; Lu et al. , 2002 ; Nash et al. , 2002 ; Keyvan-Fouladi et al. , 2003 -RRB- , primary afferents -LRB- Ramon-Cueto and Nieto-Sampedro , 1994 ; Li et al. , 2003 -RRB- and remyelination of injured/demyelinated spinal cords -LRB- Franklin et al. , 1996 ; Imaizumi et al. , 1998 ; Sasaki et al. , 2004 -RRB-	2620
the therapeutic potential	2620
olfactory bulb-derived -LRB- OB -RRB- OECs	2649
OB	2673
recovery	2693
CNS lesions to descending and ascending spinal tracts -LRB- Li et al. , 1998 ; Ramon-Cueto et al. , 2000 ; Lu et al. , 2002 ; Nash et al. , 2002 ; Keyvan-Fouladi et al. , 2003 -RRB- , primary afferents -LRB- Ramon-Cueto and Nieto-Sampedro , 1994 ; Li et al. , 2003 -RRB- and remyelination of injured/demyelinated spinal cords -LRB- Franklin et al. , 1996 ; Imaizumi et al. , 1998 ; Sasaki et al. , 2004 -RRB-	2707
CNS lesions to descending and ascending spinal tracts -LRB- Li et al. , 1998 ; Ramon-Cueto et al. , 2000 ; Lu et al. , 2002 ; Nash et al. , 2002 ; Keyvan-Fouladi et al. , 2003 -RRB-	2707
CNS lesions	2707
spinal tracts -LRB- Li et al. , 1998 ; Ramon-Cueto et al. , 2000 ; Lu et al. , 2002 ; Nash et al. , 2002 ; Keyvan-Fouladi et al. , 2003 -RRB-	2747
spinal tracts	2747
Li et al. , 1998 ; Ramon-Cueto et al. , 2000 ; Lu et al. , 2002 ; Nash et al. , 2002 ; Keyvan-Fouladi et al. , 2003	2762
Li	2762
et al. , 1998 ; Ramon-Cueto et al. , 2000 ; Lu et al. , 2002 ; Nash et al. , 2002 ; Keyvan-Fouladi et al. , 2003	2765
et al. , 1998	2765
et al.	2765
1998	2773
Ramon-Cueto et al. , 2000	2779
Ramon-Cueto	2779
et al. , 2000	2791
et al.	2791
2000	2799
Lu et al. , 2002	2805
Lu	2805
et al. , 2002	2808
et al.	2808
2002	2816
Nash et al. , 2002	2822
Nash	2822
et al. , 2002	2827
et al.	2827
2002	2835
Keyvan-Fouladi et al. , 2003	2841
Keyvan-Fouladi	2841
et al. , 2003	2856
et al.	2856
2003	2864
primary afferents -LRB- Ramon-Cueto and Nieto-Sampedro , 1994 ; Li et al. , 2003 -RRB-	2871
primary afferents	2871
Ramon-Cueto and Nieto-Sampedro , 1994 ; Li et al. , 2003	2890
Ramon-Cueto and Nieto-Sampedro	2890
1994 ; Li et al.	2922
1994	2922
Li et al.	2928
Li	2928
et al.	2931
2003	2939
remyelination of injured/demyelinated spinal cords -LRB- Franklin et al. , 1996 ; Imaizumi et al. , 1998 ; Sasaki et al. , 2004 -RRB-	2949
remyelination	2949
spinal cords -LRB- Franklin et al. , 1996 ; Imaizumi et al. , 1998 ; Sasaki et al. , 2004 -RRB-	2987
spinal cords	2987
Franklin et al. , 1996 ; Imaizumi et al. , 1998 ; Sasaki et al. , 2004	3001
Franklin	3001
et al. , 1996 ; Imaizumi et al. , 1998 ; Sasaki et al. , 2004	3010
et al. , 1996	3010
et al.	3010
1996	3018
Imaizumi et al. , 1998	3024
Imaizumi	3024
et al. , 1998	3033
et al.	3033
1998	3041
Sasaki et al. , 2004	3047
Sasaki	3047
et al. , 2004	3054
et al.	3054
2004	3062
variable yet positive outcomes	3097
Lamina propria-derived	3129
LP	3153
OECs	3157
their ability	3197
regeneration	3222
lesion -LRB- Lu et al. , 2001 , 2002 ; Ramer et al. , 2004a , b -RRB-	3241
lesion	3241
Lu et al. , 2001 , 2002 ; Ramer et al. , 2004a , b	3249
Lu et al.	3249
Lu	3249
et al.	3252
2001 , 2002 ; Ramer et al.	3260
2001 , 2002	3260
2001	3260
2002	3266
Ramer et al.	3272
Ramer	3272
et al.	3278
2004a , b	3286
2004a	3286
b	3292
the ongoing clinical use of LP tissue in spinal cord injury -LRB- SCI -RRB- treatment -LRB- Senior , 2002 ; Huang et al. , 2003 -RRB-	3304
the ongoing clinical use	3304
LP tissue in spinal cord injury -LRB- SCI -RRB- treatment -LRB- Senior , 2002 ; Huang et al. , 2003 -RRB-	3332
LP tissue	3332
spinal cord injury -LRB- SCI -RRB- treatment -LRB- Senior , 2002 ; Huang et al. , 2003 -RRB-	3345
spinal cord injury -LRB- SCI -RRB- treatment	3345
spinal cord injury -LRB- SCI -RRB-	3345
spinal cord injury	3345
SCI	3365
Senior , 2002 ; Huang et al. , 2003	3381
Senior	3381
2002 ; Huang et al.	3389
2002	3389
Huang et al.	3395
Huang	3395
et al.	3401
2003	3409
LP and OB OECs , derived from a common progenitor in the olfactory mucosa -LRB- Carter et al. , 2004 -RRB- , ensheath and promote the growth of olfactory receptor neuron axons as they exit the olfactory epithelium and extend toward theOB -LRB- Williams et al. , 2004 -RRB- .	3416
LP and OB OECs	3416
a common progenitor in the olfactory mucosa -LRB- Carter et al. , 2004 -RRB- , ensheath	3445
a common progenitor	3445
the olfactory mucosa -LRB- Carter et al. , 2004 -RRB- , ensheath	3468
the olfactory mucosa -LRB- Carter et al. , 2004 -RRB-	3468
the olfactory mucosa	3468
Carter	3490
et al. , 2004	3497
et al.	3497
2004	3505
ensheath	3512
the growth of olfactory receptor neuron axons	3533
the growth	3533
olfactory receptor neuron axons	3547
they	3582
the olfactory epithelium	3592
theOB -LRB- Williams et al. , 2004 -RRB-	3635
theOB	3635
Williams	3641
et al. , 2004	3650
et al.	3650
2004	3658
LP OECs	3668
the nerve fiber layer of the OB	3682
the nerve fiber layer	3682
the OB	3707
they	3715
OB OECs	3739
they	3754
astrocytes -LRB- Au et al. , 2002 -RRB-	3774
astrocytes	3774
Au	3786
et al. , 2002	3789
et al.	3789
2002	3797
LP and OB OECs	3819
similarities in morphology and function in vitro -LRB- Au and Roskams , 2003 ; Jani and Raisman , 2004 -RRB-	3842
similarities in morphology and function in vitro	3842
similarities	3842
morphology and function	3858
Au and Roskams , 2003 ; Jani and Raisman , 2004	3892
Au and Roskams	3892
2003 ; Jani and Raisman	3908
2003	3908
Jani and Raisman	3914
2004	3932
subtle differences in ensheathing behavior , their distinct roles in the olfactory neuraxis , and their different maturational states	3939
subtle differences	3939
behavior , their distinct roles in the olfactory neuraxis , and their different maturational states	3973
behavior	3973
their distinct roles in the olfactory neuraxis	3983
their distinct roles	3983
the olfactory neuraxis	4007
their different maturational states	4035
they	4079
different properties	4096
SCI	4141
Groups	4146
varying regeneration outcomes after dorsal rhizotomy and transplantation ofOBversus LP OECs -LRB- Ramon-Cueto and Nieto-Sampedro , 1994 ; Ramer et al. , 2004a ; Riddell et al. , 2004 -RRB-	4175
varying regeneration outcomes after dorsal rhizotomy and transplantation ofOBversus LP OECs	4175
varying regeneration outcomes	4175
dorsal rhizotomy and transplantation ofOBversus LP OECs	4211
Ramon-Cueto and Nieto-Sampedro , 1994 ; Ramer et al. , 2004a ; Riddell et al. , 2004	4268
Ramon-Cueto and Nieto-Sampedro	4268
1994 ; Ramer et al. , 2004a ; Riddell et al.	4300
1994	4300
Ramer et al. , 2004a ; Riddell et al.	4306
Ramer	4306
et al. , 2004a ; Riddell et al.	4312
et al. , 2004a	4312
et al.	4312
2004a	4320
Riddell et al.	4327
Riddell	4327
et al.	4335
2004	4343
these cases	4353
the mode of transplantation and proximity of transplanted cells to the lesion site	4366
the mode	4366
transplantation and proximity of transplanted cells to the lesion site	4378
transplantation and proximity	4378
transplanted cells to the lesion site	4411
transplanted cells	4411
the lesion site	4433
integration and long-term cell survival of transplanted cells	4465
integration and long-term cell survival	4465
transplanted cells	4508
these differences	4542
different OEC sources , methods of transplantation , and assessment measures	4575
different OEC sources	4575
methods of transplantation	4598
methods	4598
transplantation	4609
assessment measures	4630
it	4651
the regeneration-promoting abilities of LP and OB OECs	4686
the regeneration-promoting abilities	4686
LP and OB OECs	4726
the same experiment	4748
we	4775
transgenic enhanced green fluorescent protein -LRB- eGFP -RRB- - expressing OECs	4792
transgenic enhanced green fluorescent protein -LRB- eGFP -RRB-	4792
transgenic enhanced green fluorescent protein	4792
eGFP	4839
OECs	4856
the lamina propria	4866
the nerve fiber layer of the same mice	4894
the nerve fiber layer	4894
the same mice	4919
their expansion and phenotype	4953
we	4993
them	5017
a dorsolateral funiculus crush	5054
Differences examined	5086
Differences	5086
interactions	5115
host glia , their ability to promote directional angiogenesis , and their migratory properties within the spinal cord	5133
host glia	5133
their ability to promote directional angiogenesis , and their migratory properties within the spinal cord	5144
their ability to promote directional angiogenesis	5144
directional angiogenesis	5169
their migratory properties within the spinal cord	5199
their migratory properties	5199
the spinal cord	5233
we	5263
differences between LP and OB OECtreated animals	5307
differences	5307
LP and OB OECtreated animals	5327
differences	5373
autotomy resulting from transplantation of these two cell populations	5388
autotomy	5388
transplantation of these two cell populations	5412
transplantation	5412
these two cell populations	5431
Materials and Methods Cell preparation and purification .	5459
Materials and Methods	5459
Materials	5459
Methods	5473
Cell preparation and purification	5481
Cell preparation	5481
purification	5502
LP OEC cell culture	5516
GFP + LP OECs	5537
GFP	5537
LP OECs	5542
the olfactory mucosa of postnatal day 5 -LRB- P5 -RRB- transgenic mice , homozygous for eGFP -LSB- GFP-U-NAGY	5570
the olfactory mucosa of postnatal day	5570
the olfactory mucosa	5570
postnatal day	5594
5 -LRB- P5 -RRB- transgenic mice	5608
5 -LRB- P5 -RRB-	5608
transgenic mice	5615
eGFP -LSB- GFP-U-NAGY	5647
Andreas Nagy , University of Toronto , Toronto , Ontario , Canada -LRB- kind gift from Frank Jirik , University of Calgary , Calgary , Alberta , Canada -RRB- expressed under the betta-actin promoter	5678
Andreas Nagy	5678
University of Toronto , Toronto , Ontario , Canada -LRB- kind gift from Frank Jirik , University of Calgary , Calgary , Alberta , Canada -RRB- expressed under the betta-actin promoter	5692
University	5692
Toronto , Toronto , Ontario , Canada -LRB- kind gift from Frank Jirik , University of Calgary , Calgary , Alberta , Canada -RRB- expressed under the betta-actin promoter	5706
Toronto , Toronto , Ontario , Canada	5706
kind gift from Frank Jirik , University of Calgary , Calgary , Alberta , Canada	5741
kind gift from Frank Jirik	5741
kind gift	5741
Frank Jirik	5756
University of Calgary	5769
University	5769
Calgary	5783
Calgary	5792
Alberta , Canada	5801
Alberta	5801
Canada	5810
the betta-actin promoter	5834
the cytomegalovirus enhancer -LRB- Au and Roskams , 2003 -RRB-	5873
the cytomegalovirus enhancer	5873
Au and Roskams	5903
2003	5919
The entire olfactory mucosa , including turbinates and septum ,	5926
The entire olfactory mucosa	5926
turbinates and septum	5965
turbinates	5965
septum	5980
8 -- 10 pups	6007
8	6007
10 pups	6009
0.6 mg/ml collagenase D -LRB- Roche Products , Indianapolis , IN -RRB- , 3 U/ml dispase I -LRB- Roche Products -RRB- , 15 µg/ml hyaluronidase -LRB- Sigma , St. Louis , MO -RRB- , 0.5 mg/ml bovine serum albumin -LRB- MP Biomedicals , Irvine , CA -RRB- , and 100 U/ml DNase I -LRB- Sigma -RRB- for 1 h	6061
0.6 mg/ml collagenase D -LRB- Roche Products , Indianapolis , IN -RRB- , 3 U/ml dispase I -LRB- Roche Products -RRB- , 15 µg/ml hyaluronidase -LRB- Sigma , St. Louis , MO -RRB- , 0.5 mg/ml bovine serum albumin -LRB- MP Biomedicals , Irvine , CA -RRB- , and 100 U/ml DNase I -LRB- Sigma -RRB-	6061
0.6 mg/ml collagenase D -LRB- Roche Products , Indianapolis , IN -RRB- , 3 U/ml dispase I -LRB- Roche Products -RRB- , 15 µg/ml hyaluronidase -LRB- Sigma , St. Louis , MO -RRB- , 0.5 mg/ml bovine serum albumin -LRB- MP Biomedicals , Irvine , CA -RRB- , and 100 U/ml DNase I	6061
0.6 mg/ml collagenase D -LRB- Roche Products , Indianapolis , IN -RRB-	6061
0.6 mg/ml collagenase D	6061
Roche Products , Indianapolis	6086
Roche Products	6086
Indianapolis	6102
3 U/ml dispase I -LRB- Roche Products -RRB-	6121
3 U/ml dispase I	6121
Roche Products	6139
15 µg/ml hyaluronidase -LRB- Sigma , St. Louis , MO -RRB-	6156
15 µg/ml hyaluronidase	6156
Sigma	6180
St. Louis	6187
MO	6198
0.5 mg/ml bovine serum albumin -LRB- MP Biomedicals , Irvine , CA -RRB-	6203
0.5 mg/ml bovine serum albumin	6203
MP Biomedicals	6235
Irvine	6251
CA	6259
100 U/ml DNase I	6268
100 U/ml DNase	6268
I	6283
Sigma	6286
1 h	6297
37 °C	6304
centrifugation and plating	6317
Initial plating in MEM -- D-valine , 10 % fetal bovine serum -LRB- FBS -RRB- , and 100 U/ml penicillin/streptomycin -LRB- P/S -RRB-	6345
Initial plating in MEM	6345
Initial plating	6345
MEM	6364
D-valine , 10 % fetal bovine serum -LRB- FBS -RRB-	6368
D-valine	6368
10 % fetal bovine serum -LRB- FBS -RRB-	6378
10 % fetal bovine serum	6378
FBS	6402
100 U/ml penicillin/streptomycin -LRB- P/S -RRB-	6412
100 U/ml penicillin/streptomycin	6412
P/S	6446
4	6464
5 d	6466
purification using anti-Thy1.1-mediated complement lysis	6479
purification	6479
anti-Thy1.1-mediated complement lysis	6498
fibroblasts -LRB- Au and Roskams , 2003 -RRB-	6585
fibroblasts	6585
Au and Roskams	6598
2003	6614
Cells	6621
DMEM/F -12 , 10 % FBS , and 100 U/ml P/S	6644
DMEM/F -12	6644
10 % FBS	6655
100 U/ml P/S	6668
an additional 4 -- 6 d , when they were again subjected to Thy1.1-mediated complement lysis	6705
an additional 4	6705
6 d , when they were again subjected to Thy1.1-mediated complement lysis	6721
6 d	6721
they	6731
Thy1.1-mediated complement lysis	6760
LP OECs	6794
a density of 5600 cells/cm 2	6817
a density	6817
5600 cells/cm 2	6830
5600 cells/cm	6830
2	6844
T75 flasks for transplantation	6851
T75 flasks	6851
transplantation	6866
The time from dissection to transplantation	6883
The time	6883
dissection to transplantation	6897
dissection	6897
transplantation	6911
14	6939
16 d in vitro	6945
16 d	6945
DIV	6960
OB OEC cell culture	6966
the same litter of P5 eGFP transgenic mice	6992
the same litter	6992
P5 eGFP transgenic mice	7011
OB OECs	7036
the head	7083
the meningeal covering of the olfactory bulb	7102
the meningeal covering	7102
the olfactory bulb	7128
a scalpel	7154
partition the rostralmost quarter of the olfactory bulb	7167
partition	7167
the rostralmost quarter	7177
the olfactory bulb	7204
the portion of the nerve fiber layer	7239
the portion	7239
the nerve fiber layer	7254
the cribriform plate	7284
Nerve fiber layers	7306
Ramon-Cueto	7371
et al. -LRB- 1998 -RRB-	7383
et al.	7383
1998	7391
digestion by 0.1 % trypsin for 15 min at 37 °C	7407
digestion	7407
0.1 % trypsin for 15 min at 37 °C	7420
0.1 % trypsin	7420
15 min at 37 °C	7437
15 min	7437
37 °C	7447
dissociation	7468
multiple passes	7484
fire-polished pipettes	7508
the cells	7536
poly-L-lysine -LRB- PLL -RRB- -LRB- 50 µg/ml in 15 mM sodium borate buffer ; Sigma -RRB-	7563
poly-L-lysine -LRB- PLL -RRB-	7563
poly-L-lysine	7563
PLL	7578
50 µg/ml in 15 mM sodium borate buffer ; Sigma	7584
50 µg/ml	7584
15 mM sodium borate buffer ; Sigma	7596
15 mM sodium borate buffer	7596
15 mM	7596
sodium borate buffer	7602
Sigma	7624
pretreated flasks -LRB- 1 h at room temperature -RRB- containing DMEM/F -12 , supplemented with 2 mM L-glutamine , 10 % FBS , 50 µg/ml gentamycin , and 100 U/ml P/S	7631
pretreated flasks -LRB- 1 h at room temperature -RRB-	7631
pretreated flasks	7631
1 h at room temperature	7650
1 h	7650
room temperature	7657
DMEM/F -12 , supplemented with 2 mM L-glutamine , 10 % FBS , 50 µg/ml gentamycin , and 100 U/ml P/S	7686
DMEM/F -12	7686
2 mM L-glutamine , 10 % FBS , 50 µg/ml gentamycin , and 100 U/ml P/S	7715
2 mM L-glutamine	7715
10 % FBS	7733
50 µg/ml gentamycin	7742
100 U/ml P/S	7767
5 -- 6 DIV , when cells had grown to -80 % confluency	7787
5	7787
6 DIV , when cells had grown to -80 % confluency	7789
6 DIV	7789
cells	7801
-80 % confluency	7820
-80 %	7820
confluency	7825
OB OECs	7837
immunopanning	7862
Detached cells	7877
DMEM/F -12	7910
10 % FBS , and 500,000 cells were plated onto each 96mmPetri dish , pretreated with -LRB- 1 -RRB- biotinylated goat-anti rabbit IgG antibody -LRB- 3 µg/ml , 12 h , 4 °C ; Vector Laboratories , Burlingame , CA -RRB- and -LRB- 2 -RRB- rabbit anti-low-affinity nerve growth factor receptor -LRB- 1:500 , 1 h at room temperature , p75 ; Chemicon , Temecula , CA -RRB-	7925
10 % FBS	7925
500,000 cells were plated onto each 96mmPetri dish , pretreated with -LRB- 1 -RRB- biotinylated goat-anti rabbit IgG antibody -LRB- 3 µg/ml , 12 h , 4 °C ; Vector Laboratories , Burlingame , CA -RRB- and -LRB- 2 -RRB- rabbit anti-low-affinity nerve growth factor receptor -LRB- 1:500 , 1 h at room temperature , p75 ; Chemicon , Temecula , CA	7938
500,000 cells	7938
each 96mmPetri dish , pretreated with -LRB- 1 -RRB- biotinylated goat-anti rabbit IgG antibody -LRB- 3 µg/ml , 12 h , 4 °C ; Vector Laboratories , Burlingame , CA -RRB- and -LRB- 2 -RRB- rabbit anti-low-affinity nerve growth factor receptor -LRB- 1:500 , 1 h at room temperature , p75 ; Chemicon , Temecula , CA	7969
each 96mmPetri dish	7969
-LRB- 1 -RRB- biotinylated goat-anti rabbit IgG antibody -LRB- 3 µg/ml , 12 h , 4 °C ; Vector Laboratories , Burlingame , CA -RRB- and -LRB- 2 -RRB- rabbit anti-low-affinity nerve growth factor receptor -LRB- 1:500 , 1 h at room temperature , p75 ; Chemicon , Temecula , CA	8006
-LRB- 1 -RRB- biotinylated goat-anti rabbit IgG antibody -LRB- 3 µg/ml , 12 h , 4 °C ; Vector Laboratories , Burlingame , CA -RRB- and -LRB- 2 -RRB- rabbit anti-low-affinity nerve growth factor receptor -LRB- 1:500 , 1 h at room temperature , p75 ; Chemicon , Temecula ,	8006
biotinylated goat-anti rabbit	8010
IgG antibody -LRB- 3 µg/ml , 12 h ,	8040
IgG antibody	8040
3 µg/ml	8054
4 °C ; Vector Laboratories	8069
4	8069
°C	8070
Vector Laboratories	8074
Burlingame , CA -RRB- and -LRB- 2 -RRB- rabbit anti-low-affinity nerve growth factor receptor -LRB- 1:500 , 1 h	8095
Burlingame , CA -RRB- and -LRB- 2 -RRB- rabbit anti-low-affinity nerve growth factor receptor -LRB- 1:500 ,	8095
Burlingame , CA -RRB- and -LRB- 2 -RRB- rabbit anti-low-affinity nerve growth factor receptor	8095
Burlingame , CA -RRB-	8095
Burlingame	8095
-LRB- 2 -RRB- rabbit anti-low-affinity nerve growth factor receptor	8115
rabbit anti-low-affinity nerve	8119
factor receptor	8157
1:500	8174
1 h	8181
p75 ; Chemicon , Temecula ,	8206
p75	8206
Chemicon	8211
Temecula	8221
CA	8231
Cells	8236
30 min at 37 °C	8261
30 min	8261
37 °C	8271
unbound cells	8277
cells	8324
a cell lifter	8350
The 30 min immunopanning incubation	8365
30 min	8369
it	8418
the greatest purity of OB OEC cultures	8430
the greatest purity	8430
OB OEC cultures	8453
an average of 92 % p75 - positive cells -LRB- n = 4 -RRB-	8475
an average	8475
92 % p75 - positive cells -LRB- n = 4 -RRB-	8489
92 % p75	8489
positive cells	8498
n	8514
4	8516
OBOECs	8519
a density of 6500 cells/cm 2	8576
a density	8576
6500 cells/cm 2	8589
6500 cells/cm	8589
2	8603
T75 flasks for transplantation	8610
T75 flasks	8610
transplantation	8625
The time from dissection to transplantation	8642
The time	8642
dissection to transplantation	8656
dissection	8656
transplantation	8670
between 14 and 16 DIV	8690
Cell harvest for transplantation .	8713
Cell harvest	8713
transplantation	8730
transplantation	8754
the cells from one T75 flask of LP or OB OECs	8771
the cells	8771
one T75 flask of LP or OB OECs	8786
one T75 flask	8786
LP or OB OECs	8803
0.25 % trypsin/1 % EDTA	8837
0.25 %	8837
trypsin/1 %	8843
PBS and resuspension at a concentration of 50,000 -- 60,000 cells/µl in DMEM/F -12	8883
PBS	8883
resuspension at a concentration of 50,000 -- 60,000 cells/µl in DMEM/F -12	8891
resuspension at a concentration of 50,000	8891
resuspension	8891
a concentration of 50,000	8907
a concentration	8907
50,000	8926
60,000 cells/µl in DMEM/F -12	8933
60,000 cells/µl	8933
DMEM/F -12	8952
These cells	8963
two recipient rats	9010
every rat	9044
freshly harvested cells	9063
Immunocytochemistry : assessment of cell purity .	9088
Immunocytochemistry	9088
assessment of cell purity	9109
assessment	9109
cell purity	9123
LP OECs .	9136
cell purity	9155
cells	9186
typical morphology and phenotype	9200
transplantation	9240
GFP + LP OECs	9257
GFP	9257
LP OECs	9262
glass slides	9287
the second subculture	9306
4 % paraformaldehyde -LRB- PFA -RRB-	9341
4 % paraformaldehyde	9341
PFA	9362
2 DIV	9373
Purity of the culture	9380
Purity	9380
the culture	9390
the following primary antibodies incubated overnight at 4 °C : rabbit anti-p75 -LRB- 1:1000 ; Chemicon -RRB- , anti-mouse S100betta -LRB- 1:1000 ; Sigma -RRB- , and anti-glial fibrillary acidic protein -LRB- GFAP -RRB- -LRB- 1:750 ; DakoCytomation , Glostrup , Denmark -RRB-	9421
the following primary antibodies incubated overnight at 4 °C	9421
the following primary antibodies	9421
4 °C	9477
rabbit anti-p75 -LRB- 1:1000 ; Chemicon -RRB- , anti-mouse S100betta -LRB- 1:1000 ; Sigma -RRB- , and anti-glial fibrillary acidic protein -LRB- GFAP -RRB- -LRB- 1:750 ; DakoCytomation , Glostrup , Denmark -RRB-	9482
rabbit anti-p75 -LRB- 1:1000 ; Chemicon -RRB-	9482
rabbit anti-p75	9482
1:1000 ; Chemicon	9499
1:1000	9499
Chemicon	9507
anti-mouse S100betta -LRB- 1:1000 ; Sigma -RRB-	9518
anti-mouse S100betta	9518
1:1000 ; Sigma	9540
1:1000	9540
Sigma	9548
anti-glial fibrillary acidic protein -LRB- GFAP -RRB- -LRB- 1:750 ; DakoCytomation , Glostrup , Denmark -RRB-	9560
anti-glial fibrillary acidic protein -LRB- GFAP -RRB-	9560
anti-glial fibrillary acidic protein	9560
GFAP	9598
1:750 ; DakoCytomation , Glostrup , Denmark	9605
1:750	9605
DakoCytomation , Glostrup , Denmark	9612
Slides	9648
1 h at room temperature with Alexa 594 goat secondary antibodies -LRB- 1:100 ; Jackson ImmunoResearch , Mississauga , Ontario , Canada -RRB- in 2 % goat serum , followed by a 10 min incubation in 0.5 µg/ml 4-,6-diamidine-2-phenylindole dihydrochloride -LRB- DAPI -RRB- -LRB- Boehringer Mannheim , Mannheim , Germany -RRB- , and coverslipped in Vectashield mounting media -LRB- Vector Laboratories -RRB-	9679
1 h	9679
room temperature with Alexa 594 goat secondary antibodies -LRB- 1:100 ; Jackson ImmunoResearch , Mississauga , Ontario , Canada -RRB- in 2 % goat serum , followed by a 10 min incubation in 0.5 µg/ml 4-,6-diamidine-2-phenylindole dihydrochloride -LRB- DAPI -RRB- -LRB- Boehringer Mannheim , Mannheim , Germany -RRB- , and coverslipped in Vectashield mounting media -LRB- Vector Laboratories -RRB-	9686
room temperature with Alexa 594 goat secondary antibodies -LRB- 1:100 ; Jackson ImmunoResearch , Mississauga , Ontario , Canada -RRB-	9686
room temperature with Alexa 594 goat secondary antibodies	9686
room temperature with Alexa 594 goat	9686
room temperature	9686
Alexa 594 goat	9708
1:100 ; Jackson ImmunoResearch , Mississauga , Ontario , Canada	9745
1:100	9745
Jackson ImmunoResearch , Mississauga , Ontario , Canada	9752
2 % goat serum , followed by a 10 min incubation in 0.5 µg/ml 4-,6-diamidine-2-phenylindole dihydrochloride -LRB- DAPI -RRB- -LRB- Boehringer Mannheim , Mannheim , Germany -RRB- , and coverslipped in Vectashield mounting media	9809
2 % goat serum	9809
a 10 min incubation in 0.5 µg/ml 4-,6-diamidine-2-phenylindole dihydrochloride -LRB- DAPI -RRB- -LRB- Boehringer Mannheim , Mannheim , Germany -RRB-	9836
a 10 min incubation	9836
0.5 µg/ml 4-,6-diamidine-2-phenylindole dihydrochloride -LRB- DAPI -RRB- -LRB- Boehringer Mannheim , Mannheim , Germany -RRB-	9859
0.5 µg/ml 4-,6-diamidine-2-phenylindole dihydrochloride -LRB- DAPI -RRB-	9859
0.5 µg/ml 4-,6-diamidine-2-phenylindole dihydrochloride	9859
0.5 µg/ml	9859
DAPI	9916
Boehringer Mannheim	9923
Mannheim	9944
Germany	9954
Vectashield mounting media	9984
Vector Laboratories	10012
OB OECs .	10034
the optimal time and antibody concentrations for immunopanning	10067
the optimal time and antibody concentrations	10067
immunopanning	10116
OB OEC purity	10131
different panning conditions	10169
glass slides	10203
rabbit anti-p75 -LRB- 1:1000 ; Chemicon -RRB- , as well as secondary antibodies and DAPI	10250
rabbit anti-p75 -LRB- 1:1000 ; Chemicon -RRB-	10250
rabbit anti-p75	10250
1:1000 ; Chemicon	10267
1:1000	10267
Chemicon	10275
secondary antibodies and DAPI	10297
secondary antibodies	10297
DAPI	10322
DAPI nuclei	10347
as well as p75 + cells to assess for the enrichment of p75 + cells	10373
p75	10384
cells to assess for the enrichment of p75 + cells	10389
the enrichment of p75 + cells	10409
the enrichment	10409
p75 + cells	10427
p75	10427
cells	10432
cell purification procedures	10456
allOBOECcell cultures	10486
the same slide generation	10531
second subculture and immunocytochemistry	10563
LP OECs	10628
In vitro migration assays .	10637
In vitro migration	10637
assays	10656
LP or OB OECs cultured for the same DIV	10664
LP or OB OECs	10664
the same DIV	10691
passage 2	10722
Boyden chambers pretreated with PLL -LRB- 50µg/ml in borate buffer , 1 h at room temperature -RRB- or laminin -LRB- 1 µg/ml in PBS , 1 h at 37 °C -RRB- in 24-well plates at a density of 5000 cells/well	10748
Boyden chambers	10748
PLL -LRB- 50µg/ml in borate buffer , 1 h at room temperature -RRB- or laminin -LRB- 1 µg/ml in PBS , 1 h at 37 °C -RRB-	10780
PLL	10780
50µg/ml in borate buffer , 1 h at room temperature	10785
50µg/ml	10785
borate buffer , 1 h at room temperature	10796
borate buffer	10796
1 h at room temperature	10811
1 h	10811
room temperature	10818
laminin	10839
1 µg/ml in PBS , 1 h at 37 °C	10848
1 µg/ml	10848
PBS , 1 h at 37 °C	10859
PBS	10859
1 h at 37 °C	10864
1 h	10864
37 °C	10871
24-well plates	10880
a density of 5000 cells/well	10898
a density	10898
5000 cells/well	10911
The main well	10928
2.5 % FBS	10952
DMEM/F -12	10964
Cells	10975
20 h	10994
the top sides of experimental transwells	11000
the top sides	11000
experimental transwells	11017
both sides	11060
negative controls	11088
neither side	11111
positive controls	11140
Transwells	11159
0.1 % glutaraldehyde in 4 % PFA in PBS	11184
0.1 % glutaraldehyde	11184
4 % PFA in PBS	11207
4 % PFA	11207
PBS	11217
30 min at room temperature	11225
30 min	11225
room temperature	11235
Membranes	11253
DAPI , mounted onto glass slides , coverslipped with Vectashield -LRB- Vector Laboratories -RRB-	11286
DAPI	11286
glass slides	11305
Vectashield -LRB- Vector Laboratories -RRB-	11337
Vectashield	11337
Vector Laboratories	11350
5x images	11376
the entire membrane	11415
DAPI + nuclei	11436
DAPI	11436
nuclei	11442
migration values	11467
a percentage of total cells on positive membranes -LRB- experimental minus negative counts divided by the total cells on positive membranes -RRB-	11502
a percentage	11502
total cells on positive membranes -LRB- experimental minus negative counts divided by the total cells on positive membranes -RRB-	11518
total cells	11518
positive membranes	11533
experimental minus negative counts divided by the total cells on positive membranes	11553
experimental	11553
negative counts	11572
the total cells on positive membranes	11599
the total cells	11599
positive membranes	11618
Spinal cord injury and cell transplantation .	11639
Spinal cord	11639
injury and cell transplantation	11651
Dorsolateral funiculus crush .	11684
Dorsolateral funiculus	11684
crush	11707
Animal procedures	11714
accordance	11750
the guidelines of the Canadian Council for Animal Care	11766
the guidelines	11766
the Canadian Council for Animal Care	11784
the Canadian Council	11784
Animal Care	11809
the Animal Care Committee of the University of British Columbia	11842
the Animal Care Committee	11842
the University of British Columbia	11871
the University	11871
British Columbia	11889
Forty-two adult male Sprague Dawley rats -LRB- 150 -- 200 g ; Charles River Laboratories , Wilmington , MA -RRB-	11907
Forty-two adult male Sprague Dawley rats	11907
150	11949
200 g ; Charles River Laboratories , Wilmington , MA	11953
200 g	11953
Charles River Laboratories , Wilmington , MA	11960
Charles River Laboratories	11960
Wilmington , MA	11988
cyclosporine A -LRB- 10 mg * kg-1	12031
cyclosporine A -LRB- 10 mg	12031
cyclosporine A	12031
10 mg	12047
10	12047
mg	12050
kg-1	12055
d-1 , i.p. ; Novartis Pharmaceuticals , Mississauga , Ontario , Canada -RRB- 2 d before surgery and each day	12062
d-1 , i.p. ; Novartis Pharmaceuticals , Mississauga , Ontario , Canada -RRB- 2 d	12062
d-1 , i.p. ; Novartis Pharmaceuticals , Mississauga , Ontario , Canada -RRB-	12062
d-1 , i.p.	12062
d-1	12062
Novartis Pharmaceuticals , Mississauga , Ontario , Canada	12073
Novartis Pharmaceuticals	12073
Mississauga , Ontario , Canada	12099
surgery and each day	12140
surgery	12140
each day	12152
the duration of the experiment	12165
the duration	12165
the experiment	12181
anaesthetization with xylazine/ketamine -LRB- 10 and 70 mg/kg , i.p. -RRB-	12203
anaesthetization	12203
xylazine/ketamine -LRB- 10 and 70 mg/kg , i.p. -RRB-	12225
xylazine/ketamine	12225
10 and 70 mg/kg , i.p.	12244
10 and 70 mg/kg	12244
10	12244
70 mg/kg	12251
a hemilaminectomy	12268
the left halves of the third and fourth cervical segments	12310
the left halves	12310
the third and fourth cervical segments	12329
The dura	12369
microscissors	12396
the spinal cord	12420
one prong of custom-designed fine surgical forceps	12441
one prong	12441
custom-designed fine surgical forceps	12454
the gray and white matter	12513
the other prong outside the dorsolateral funiculus	12545
the other prong	12545
the dorsolateral funiculus	12569
a depth of 1 mm	12600
a depth	12600
1 mm	12611
The forceps	12617
18	12650
20 s , crushing the dorsolateral funiculus	12653
20 s	12653
the dorsolateral funiculus	12668
Previous studies in our laboratory	12696
Previous studies	12696
our laboratory	12716
this injury	12751
all rubrospinal axons -LRB- Ramer et al. , 2004 -RRB-	12779
all rubrospinal axons	12779
Ramer	12802
et al. , 2004	12808
et al.	12808
2004	12816
Crush treatment	12823
animals	12868
cell transplantation and control groups	12895
crush	12941
Cell transplantation .	12948
Cell	12948
transplantation	12953
LP or OB OEC cell slurries in DMEM/F -12	12970
LP	12970
OB OEC cell slurries in DMEM/F -12	12976
OB OEC cell slurries	12976
DMEM/F -12	13000
a pulled glass pipette with a diameter of 20µm in a Hamilton syringe	13026
a pulled glass pipette	13026
a diameter of 20µm in a Hamilton syringe	13054
a diameter	13054
20µm in a Hamilton syringe	13068
20µm	13068
a Hamilton syringe	13076
OECs	13096
-LRB- 1 -RRB- within the lesion site over three injection points , at a depth of 0.7 , 1.0 , and 1.5 mm , dividing the cell suspension equally between these three points , or -LRB- 2 -RRB- 1 mm rostral and caudal -LRB- R/C -RRB- to the lesion site at a depth of 0.6 and 1.2 mm , dividing the suspension equally between four points -LRB- diagrammed in supplemental Fig. 1 , available at www.jneurosci.org as supplemental material -RRB-	13143
-LRB- 1 -RRB- within the lesion site over three injection points , at a depth of 0.7 , 1.0 , and 1.5 mm , dividing the cell suspension equally between these three points	13143
within the lesion	13147
site	13165
three injection points , at a depth of 0.7 , 1.0 , and 1.5 mm , dividing the cell suspension equally between these three points	13175
three injection points	13175
a depth of 0.7 , 1.0 , and 1.5 mm	13202
a depth	13202
0.7 , 1.0 , and 1.5 mm	13213
0.7	13213
1.0	13218
1.5 mm	13227
the cell suspension	13244
these three points	13280
-LRB- 2 -RRB- 1 mm rostral and caudal -LRB- R/C -RRB- to the lesion site at a depth of 0.6 and 1.2 mm , dividing the suspension equally between four points -LRB- diagrammed in supplemental Fig. 1 , available at www.jneurosci.org as supplemental material -RRB-	13303
1 mm	13307
rostral and caudal -LRB- R/C -RRB- to the lesion site at a depth of 0.6 and 1.2	13312
rostral and caudal -LRB- R/C -RRB-	13312
rostral and caudal	13312
R/C	13332
the lesion site	13340
a depth	13359
0.6 and 1.2	13370
mm , dividing the suspension equally between four points -LRB- diagrammed in supplemental Fig. 1 , available at www.jneurosci.org as supplemental material -RRB-	13382
mm	13382
the suspension	13395
four points -LRB- diagrammed in supplemental Fig. 1 , available at www.jneurosci.org as supplemental material -RRB-	13426
four points	13426
supplemental Fig. 1 , available at www.jneurosci.org	13453
supplemental Fig. 1	13453
www.jneurosci.org	13487
supplemental material	13508
A total of 1.5 µl of cell slurry	13532
A total	13532
1.5 µl of cell slurry	13543
1.5 µl	13543
cell slurry	13553
a rate of 100 nl/min	13581
a rate	13581
100 nl/min	13591
each rat	13611
a total of 75,000 -- 90,000 cells	13629
a total of 75,000	13629
a total	13629
75,000	13640
90,000 cells	13648
Control animals	13662
the same volume of DMEM/F -12	13687
the same volume	13687
DMEM/F -12	13706
the same sites	13728
the same rate	13746
The glass pipette	13761
place for 5 min	13791
place	13791
5 min	13801
each injection	13813
cells	13843
the spinal cord	13861
the syringe	13905
injection	13924
the pipette	13935
the muscle and skin	13975
interrupted sutures	14012
The 28 d survival groups	14033
direct LP OEC , n = 5 ; R/C LP OEC , n = 4 ; direct OB OEC , n = 4 ; R/C OB OEC , n = 4 ; direct control , n	14075
direct LP OEC	14075
n = 5 ; R/C LP OEC , n = 4 ; direct OB OEC , n = 4 ; R/C OB OEC , n = 4 ; direct control , n	14090
n = 5	14090
n	14090
5	14092
R/C LP OEC , n = 4	14095
R/C LP OEC	14095
n = 4	14107
n	14107
4	14111
direct OB OEC , n = 4	14114
direct OB OEC	14114
n = 4	14129
n	14129
4	14133
R/C OB OEC , n = 4	14136
R/C OB OEC	14136
n = 4	14148
n	14148
4	14152
direct control , n	14155
direct control	14155
n	14171
4	14175
R/C control	14182
n = 4	14195
n	14195
4	14199
The 24 h survival groups	14202
direct LP OEC , n = 3 ; R/C LP OEC , n = 5 ; R/C OB OEC , n	14244
direct LP OEC	14244
n = 3 ; R/C LP OEC , n = 5 ; R/C OB OEC , n	14259
n = 3	14259
n	14259
3	14261
R/C LP OEC , n = 5	14264
R/C LP OEC	14264
n = 5	14276
n	14276
5	14278
R/C OB OEC , n	14281
R/C OB OEC	14281
n	14293
4	14295
R/C control	14302
n = 5	14315
n	14315
5	14319
Immunohistochemistry .	14322
24 h or 28 d after SCI and transplantation	14347
24 h	14347
28 d after SCI and transplantation	14355
28 d	14355
SCI and transplantation	14366
SCI	14366
transplantation	14374
animals	14391
a lethal overdose of chloral hydrate -LRB- 100 mg/kg , i.p. -RRB-	14416
a lethal overdose	14416
chloral hydrate -LRB- 100 mg/kg , i.p. -RRB-	14437
chloral hydrate	14437
100 mg/kg , i.p.	14454
100 mg/kg	14454
PBS	14504
4 % PFA	14521
pH 7.4	14529
Cervical spinal cords and brain	14537
successive sucrose sinking in 12 , 18 , and 24 % sucrose in PBS	14604
successive sucrose sinking	14604
12 , 18 , and 24 % sucrose in PBS	14634
12	14634
18	14638
24 % sucrose in PBS	14646
24 % sucrose	14646
PBS	14661
24 h each	14669
24 h	14669
each	14674
freezing in Tissue-Tek	14692
freezing	14692
Tissue-Tek	14704
optimal cutting temperature compound -LRB- Sakura , Tokyo , Japan -RRB- in isopentane	14715
optimal cutting temperature compound	14715
Sakura	14753
Tokyo	14761
Japan	14768
isopentane	14778
dry ice	14794
Sections of spinal cord	14803
Sections	14803
spinal cord	14815
14 µm	14845
-20 °C	14865
Standard immunohistochemical procedures used for most detection	14872
Standard immunohistochemical procedures	14872
most detection	14921
sections	14953
the slide	14989
10 min , followed by postfixation in 4 % PFA for 10 min , 30 min of permeabilization in 0.01 % Triton X-100 , 20 min block in 4 % normal goat serum in PBS , and incubation of primary antibody overnight at 4 °C in 2 % serum	15014
10 min	15014
postfixation in 4 % PFA for 10 min , 30 min of permeabilization in 0.01 % Triton X-100 , 20 min block in 4 % normal goat serum in PBS , and incubation of primary antibody	15034
postfixation	15034
4 % PFA for 10 min , 30 min of permeabilization in 0.01 % Triton X-100 , 20 min block in 4 % normal goat serum in PBS , and incubation of primary antibody	15050
4 % PFA for 10 min	15050
4 % PFA	15050
10 min	15061
30 min of permeabilization in 0.01 % Triton X-100	15069
30 min of permeabilization in 0.01 %	15069
30 min	15069
permeabilization in 0.01 %	15079
permeabilization	15079
0.01 %	15099
Triton X-100	15105
20 min block in 4 % normal goat serum in PBS	15119
20 min block	15119
4 % normal goat serum	15135
PBS	15159
incubation of primary antibody	15168
incubation	15168
primary antibody	15182
4 °C in 2 % serum	15212
4 °C	15212
2 % serum	15219
The following primary antibodies	15229
: GFAP -LRB- 1:400 ; DakoCytomation -RRB- , rabbit anti-p75 -LRB- 1:500 ; Chemicon -RRB- S100 -LRB- 1 : 1000 ; Sigma -RRB- , mouse anti-p75 -LRB- mp75 -RRB- -LRB- 1:50 ; Chemicon -RRB- , rat endothelial cell antigen -LRB- RECA -RRB- -LRB- 1:50 ; Serotec , Oxford , UK -RRB- , laminin -LRB- 1:1000 ; Sigma -RRB- , neurofilament heavy chain -LRB- NF -RRB- -LRB- 1:500 ; Serotec -RRB- , tyrosine hydroxylase -LRB- TH -RRB- -LRB- 1:250 ; Chemicon -RRB- , substance P -LRB- subP -RRB- -LRB- 1:1000 ; Chemicon -RRB- , serotonin -LRB- 5-HT -RRB- -LRB- 1:8000 ; ImmunoStar , Hudson , WI -RRB- , calcitonin gene-related peptide -LRB- CGRP -RRB- -LRB- 1:200 ; Sigma -RRB- , and streptomycin -- cyanine 3 -LRB- 1:250 ; Jackson ImmunoResearch -RRB-	15279
GFAP -LRB- 1:400 ; DakoCytomation -RRB- , rabbit anti-p75 -LRB- 1:500 ; Chemicon -RRB- S100 -LRB- 1 : 1000 ; Sigma -RRB- , mouse anti-p75 -LRB- mp75 -RRB- -LRB- 1:50 ; Chemicon -RRB- , rat endothelial cell antigen -LRB- RECA -RRB- -LRB- 1:50 ; Serotec , Oxford , UK -RRB- , laminin -LRB- 1:1000 ; Sigma -RRB- , neurofilament heavy chain -LRB- NF -RRB- -LRB- 1:500 ; Serotec -RRB- , tyrosine hydroxylase -LRB- TH -RRB- -LRB- 1:250 ; Chemicon -RRB- , substance P -LRB- subP -RRB- -LRB- 1:1000 ; Chemicon -RRB- , serotonin -LRB- 5-HT -RRB- -LRB- 1:8000 ; ImmunoStar , Hudson , WI -RRB- , calcitonin gene-related peptide -LRB- CGRP -RRB- -LRB- 1:200 ; Sigma -RRB- , and streptomycin	15281
GFAP -LRB- 1:400 ; DakoCytomation -RRB-	15281
GFAP	15281
1:400 ; DakoCytomation	15287
1:400	15287
DakoCytomation	15294
rabbit anti-p75 -LRB- 1:500 ; Chemicon -RRB- S100 -LRB- 1 : 1000 ; Sigma -RRB-	15311
rabbit anti-p75 -LRB- 1:500 ; Chemicon -RRB- S100	15311
rabbit anti-p75 -LRB- 1:500 ; Chemicon -RRB-	15311
rabbit anti-p75	15311
1:500 ; Chemicon	15328
1:500	15328
Chemicon	15335
1 : 1000 ; Sigma	15352
1 : 1000	15352
Sigma	15361
mouse anti-p75 -LRB- mp75 -RRB- -LRB- 1:50 ; Chemicon -RRB-	15369
mouse anti-p75 -LRB- mp75 -RRB-	15369
mouse anti-p75	15369
mp75	15385
1:50 ; Chemicon	15392
1:50	15392
Chemicon	15398
rat endothelial cell antigen -LRB- RECA -RRB- -LRB- 1:50 ; Serotec , Oxford , UK -RRB-	15409
rat endothelial cell antigen -LRB- RECA -RRB-	15409
rat	15409
endothelial cell antigen -LRB- RECA -RRB-	15413
endothelial cell antigen	15413
RECA	15439
1:50 ; Serotec , Oxford , UK	15446
1:50	15446
Serotec , Oxford , UK	15452
laminin -LRB- 1:1000 ; Sigma -RRB-	15474
laminin	15474
1:1000 ; Sigma	15483
1:1000	15483
Sigma	15491
neurofilament heavy chain -LRB- NF -RRB- -LRB- 1:500 ; Serotec -RRB-	15499
neurofilament heavy chain -LRB- NF -RRB-	15499
neurofilament heavy chain	15499
NF	15526
1:500 ; Serotec	15531
1:500	15531
Serotec	15538
tyrosine hydroxylase -LRB- TH -RRB- -LRB- 1:250 ; Chemicon -RRB-	15548
tyrosine hydroxylase -LRB- TH -RRB-	15548
tyrosine hydroxylase	15548
TH	15570
1:250 ; Chemicon	15575
1:250	15575
Chemicon	15582
substance P -LRB- subP -RRB- -LRB- 1:1000 ; Chemicon -RRB-	15593
substance P -LRB- subP -RRB-	15593
substance P	15593
subP	15606
1:1000 ; Chemicon	15613
1:1000	15613
Chemicon	15621
serotonin -LRB- 5-HT -RRB- -LRB- 1:8000 ; ImmunoStar , Hudson , WI -RRB-	15632
serotonin -LRB- 5-HT -RRB-	15632
serotonin	15632
5-HT	15643
1:8000 ; ImmunoStar , Hudson , WI	15650
1:8000	15650
ImmunoStar , Hudson , WI	15658
calcitonin gene-related peptide -LRB- CGRP -RRB- -LRB- 1:200 ; Sigma -RRB-	15683
calcitonin gene-related peptide -LRB- CGRP -RRB-	15683
calcitonin gene-related peptide	15683
CGRP	15716
1:200 ; Sigma	15723
1:200	15723
Sigma	15730
streptomycin	15742
cyanine 3 -LRB- 1:250 ; Jackson ImmunoResearch -RRB-	15756
cyanine 3	15756
1:250 ; Jackson ImmunoResearch	15767
1:250	15767
Jackson ImmunoResearch	15774
Secondary antibodies raised in goat and conjugated to Alexa 350 , 488 , or 594	15799
Secondary antibodies raised in goat and conjugated to Alexa 350 , 488	15799
Secondary antibodies	15799
goat	15830
Alexa 350 , 488	15853
594	15872
1 h at room temperature	15893
1 h	15893
room temperature	15900
sections	15922
Vectashield -LRB- Vector Laboratories -RRB-	15957
Vectashield	15957
Vector Laboratories	15970
Image analysis and quantification .	15992
Image	15992
analysis and quantification	15998
Z-stacked 200x or 100x , montaged digital images	16027
Z-stacked 200x	16027
100x , montaged digital images	16045
an Axioplan 2 microscope -LRB- Zeiss , Jena , Germany -RRB- , a digital camera -LRB- QImaging , Burnaby , British Columbia , Canada -RRB- , and Northern Eclipse software -LRB- Empix Imaging , Mississauga , Ontario , Canada -RRB-	16094
an Axioplan 2 microscope -LRB- Zeiss , Jena , Germany -RRB-	16094
an Axioplan 2 microscope	16094
Zeiss	16120
Jena	16127
Germany	16133
a digital camera -LRB- QImaging , Burnaby , British Columbia , Canada -RRB-	16143
a digital camera	16143
QImaging , Burnaby , British Columbia , Canada	16161
QImaging	16161
Burnaby	16171
British Columbia	16180
Canada	16198
Northern Eclipse software -LRB- Empix Imaging , Mississauga , Ontario , Canada -RRB-	16211
Northern Eclipse software	16211
Empix Imaging	16238
Mississauga	16253
Ontario , Canada	16266
Northern Eclipse , Photoshop 7.0 -LRB- Adobe Systems , San Jose , CA -RRB- , and SigmaScan Pro -LRB- SPSS , Chicago , IL -RRB-	16308
Northern Eclipse	16308
Photoshop 7.0 -LRB- Adobe Systems , San Jose , CA -RRB-	16326
Photoshop 7.0	16326
Adobe Systems	16341
San Jose	16356
CA	16366
SigmaScan Pro -LRB- SPSS , Chicago , IL -RRB-	16375
SigmaScan	16375
Pro -LRB- SPSS , Chicago , IL -RRB-	16385
Pro	16385
SPSS	16390
Chicago	16396
IL	16405
software	16409
Lesion area and cavity size	16419
Lesion area	16419
cavity size	16435
each animal	16467
the lesion area defined by GFAP at three defined levels , 0.65 , 0.9 , and 1.15 mm ventral in the spinal cord	16492
the lesion area	16492
GFAP	16519
three defined levels , 0.65 , 0.9 , and 1.15 mm ventral in the spinal cord	16527
three	16527
levels , 0.65 , 0.9 , and 1.15 mm ventral in the spinal cord	16541
levels	16541
0.65	16549
0.9	16555
1.15 mm ventral in the spinal cord	16564
1.15 mm	16564
the spinal cord	16583
the total pixels in this area	16616
the total pixels	16616
this area	16636
GFAP immunodensitometry	16647
sections at 0.9 mm ventral for all animals in each treatment group	16688
sections	16688
0.9 mm ventral for all animals in each treatment group	16700
0.9 mm	16700
all animals in each treatment group	16718
all animals	16718
each treatment group	16733
a defined area size around the lesion site compared with the analogous area on the contralateral uninjured side of the spinal cord	16777
a defined area size	16777
the lesion site compared with the analogous area on the contralateral uninjured side of the spinal cord	16804
the lesion site	16804
the analogous area on the contralateral uninjured side of the spinal cord	16834
the analogous area	16834
the contralateral uninjured side of the spinal cord	16856
the contralateral uninjured side	16856
the spinal cord	16892
Autofluorescent items	16909
triplefluorescing items in black	16964
triplefluorescing items	16964
black	16991
All axon quantitation	16998
the three depths	17037
the spinal cord named above Quantitation within the lesion site was performed by outlining the GFAP-reactive border , binning fluorescence from axon staining into four bins -LRB- to normalize staining between animals -RRB-	17057
the spinal cord	17057
Quantitation	17085
the lesion site was performed by outlining the GFAP-reactive border , binning fluorescence from axon staining into four bins -LRB- to normalize staining between animals -RRB-	17105
the lesion site was performed by outlining the GFAP-reactive border	17105
the lesion site	17105
the GFAP-reactive border	17148
binning fluorescence from axon staining into four bins -LRB- to normalize staining between animals -RRB-	17174
binning fluorescence	17174
axon staining	17200
four bins	17219
staining between animals	17243
staining	17243
animals	17260
the number of pixels in the top three bins	17274
the number	17274
pixels in the top three bins	17288
pixels	17288
the top three bins	17298
areas on either side of the lesion site	17335
areas	17335
either side of the lesion site	17344
either side	17344
the lesion site	17359
selection areas measuring 750,000 pixels at 0.5 and 1 mm rostral/caudal to the rostra / caudal lesion boundary were quantified as described for within lesion measured	17384
selection areas	17384
750,000 pixels	17410
0.5 and 1 mm rostral/caudal to the rostra / caudal lesion boundary were quantified as described for within lesion measured	17428
0.5 and 1 mm rostral/caudal to the rostra	17428
0.5 and 1 mm rostral/caudal	17428
the rostra	17459
caudal lesion boundary	17471
lesion measured	17534
lesion	17534
pixels in the three top bins	17575
pixels	17575
the three top bins	17585
A similar strategy	17605
GFP + items at locations within the lesion site , or 0.5	17645
GFP + items	17645
locations within the lesion site , or 0.5	17659
locations within the lesion site	17659
locations	17659
the lesion site	17676
0.5	17696
the lesion site	17729
Items fluorescing in all three channels	17746
Items	17746
all three channels	17767
the number of GFP + pixels	17810
the number	17810
GFP + pixels	17824
GFP	17824
pixels	17829
selection areas	17856
750,000 pixels	17882
Analysis of angiogenesis and directionality	17898
Analysis	17898
angiogenesis and directionality	17910
programs designed on Matlab -LRB- MathWorks , Natick , MA -RRB-	17963
programs	17963
Matlab -LRB- MathWorks , Natick , MA -RRB-	17984
Matlab	17984
MathWorks	17992
Natick	18003
MA	18011
100x montaged images stained with anti-RECA	18025
100x montaged images	18025
anti-RECA	18059
two levels	18102
blood vessels above a threshold size	18114
blood vessels	18114
a threshold size	18134
a best-fit line	18192
Intersection points from lines	18221
Intersection points	18221
lines	18246
the same x -- y plane as the original image	18274
the same x	18274
y plane as the original image	18285
y plane	18285
the original image	18296
the number of intersection points in the lesion site , as defined by an outline of the GFAP scar ,	18320
the number	18320
intersection points in the lesion site	18334
intersection points	18334
the lesion site	18357
an outline of the GFAP scar	18388
an outline	18388
the GFAP scar	18402
The scar area	18431
the image 100 times	18494
the image	18494
100 times	18504
a baseline value of directionality	18527
a baseline value	18527
directionality	18547
The ratio of directionality in the lesion and at the random points	18563
The ratio	18563
directionality in the lesion and at the random points	18576
directionality	18576
the lesion	18594
the random points	18612
t tests	18643
appropriate , orANOVAsfollowed by post hoc analysis using Tukey 's tests	18666
appropriate	18666
post hoc analysis	18699
Tukey 's tests	18723
Tukey 's	18723
groups	18765
Graphical data	18773
error bars	18807
SEM	18831
Results Figure 1 .	18837
Results	18837
Figure 1	18845
LP and OB OECs	18855
similar antigenic and morphological properties	18878
14 DIV	18941
GFP + LP -LRB- A -RRB- and OB -LRB- B -RRB- OECs	18949
GFP	18949
LP -LRB- A -RRB-	18954
LP	18954
A	18958
OB -LRB- B -RRB- OECs	18965
OB	18965
B	18969
OECs	18972
p75 and S100betta -LRB- C , D -RRB-	18985
p75 and S100betta	18985
primarily a flattened -LRB- arrow -RRB- morphology , with some fusiform cells -LRB- arrowhead -RRB-	19019
primarily a	19019
arrow	19042
morphology	19049
some fusiform cells -LRB- arrowhead -RRB-	19066
some fusiform cells	19066
arrowhead	19087
Scale bars , 100µm .	19107
Scale bars	19107
100µm	19119
Figure 2 .	19127
Figure	19127
2	19134
LP OECs and OB OECs	19137
LP OECs	19137
OB OECs	19149
their ability to migrate in vivo and in vitro	19167
vivo	19195
28 d after lesion	19217
28 d	19217
lesion	19228
R/C transplanted GFP + LP OECs -LRB- A -RRB-	19236
R/C	19236
GFP + LP OECs	19253
GFP	19253
LP OECs	19258
A	19267
their injection points -LRB- asterisk -RRB-	19283
their injection points	19283
asterisk	19307
the lesion site -LRB- arrowhead -RRB- , denoted by GFAP immunoreaction -LRB- red pseudocolor -RRB- ,	19327
the lesion site	19327
arrowhead	19344
GFAP immunoreaction -LRB- red pseudocolor -RRB-	19367
GFAP immunoreaction	19367
red pseudocolor	19388
R/C transplanted GFP + OB OECs -LRB- B -RRB-	19414
R/C	19414
GFP + OB OECs	19431
B	19445
injection points and lesion site -LRB- n = 4 of 4 animals with surviving GFP + cells -RRB-	19468
injection points and lesion site	19468
injection points	19468
lesion site	19489
n = 4 of 4 animals with surviving GFP + cells	19502
n	19502
= 4	19503
4 animals with surviving GFP + cells	19509
4 animals	19509
GFP + cells	19534
GFP	19534
cells	19539
The larger area occupied by OB OECs -LRB- B -RRB-	19547
The larger area	19547
OB OECs -LRB- B -RRB-	19575
OB OECs	19575
B	19584
R/C LP OECs	19607
7 d -LRB- C -RRB-	19622
7 d	19622
C	19627
D , Quantitative assessment of GFP + LP and OB OECs -LRB- in pixels -RRB- at 1 and 0.5 mm rostral/caudal and within the lesion site	19631
D	19631
Quantitative assessment of GFP + LP and OB OECs -LRB- in pixels -RRB- at 1 and 0.5 mm rostral/caudal and within the lesion site	19634
Quantitative assessment of GFP	19634
Quantitative assessment	19634
GFP	19661
LP and OB OECs -LRB- in pixels -RRB- at 1 and 0.5 mm rostral/caudal and within the lesion site	19666
LP and OB OECs -LRB- in pixels -RRB-	19666
LP and OB OECs	19666
pixels	19685
1 and 0.5 mm rostral/caudal	19696
the lesion site	19735
significantly more GFP	19759
cells at 0.5 and 1mmcaudal in OB-treated rats	19783
cells	19783
0.5 and 1mmcaudal	19792
OB-treated rats	19813
LP OEC-treated rats -LRB- p ≤ 0.05 -RRB-	19837
LP OEC-treated rats	19837
p ≤ 0.05	19859
p	19859
≤ 0.05	19860
E , In vitro ,	19868
E	19868
a Boyden chamber migration assay	19887
OB OECs	19921
60 %	19937
LP OECs	19951
20 h on PLL	19965
20 h	19965
PLL	19973
the migratory difference	19982
laminin	20025
OB OECs migrating 85 % less than LP OECs -LRB- n = 3 ; p ≤ 0.02 , all groups -RRB-	20038
OB OECs	20038
85 %	20056
LP OECs -LRB- n = 3 ; p ≤ 0.02 , all groups -RRB-	20070
LP OECs	20070
n = 3 ; p ≤ 0.02 , all groups	20079
n = 3 ; p ≤ 0.02 , all	20079
n = 3	20079
n	20079
3	20081
p ≤ 0.02 , all	20084
p	20084
≤ 0.02	20085
groups	20096
Data	20105
mean ± SEM	20127
Scale bars , 250µm .	20138
Scale bars	20138
250µm	20150
Figure 3 .	20158
Figure	20158
3	20165
Lesion site area and cavity formation	20168
Lesion site area	20168
cavity formation	20189
LP	20223
OB-treated rats	20234
Astrogliosis	20251
direct transplantation	20280
Examples of the lesion site	20304
Examples	20304
the lesion site	20316
area , visualized by anti-GFAP -LRB- red pseudocolor -RRB- and cavities 28 d after transplantation of GFP + OB OECs directly -LRB- A -RRB- and rostrocaudally -LRB- B -RRB- or GFP + LP OECs directly -LRB- C -RRB- and rostrocaudally	20332
area , visualized by anti-GFAP -LRB- red pseudocolor -RRB- and cavities 28 d after transplantation of GFP + OB OECs directly -LRB- A -RRB- and rostrocaudally -LRB- B -RRB- or GFP + LP OECs directly -LRB- C -RRB-	20332
area	20332
anti-GFAP -LRB- red pseudocolor -RRB- and cavities 28 d after transplantation of GFP + OB OECs directly -LRB- A -RRB- and rostrocaudally -LRB- B -RRB- or GFP + LP OECs directly -LRB- C -RRB-	20352
anti-GFAP -LRB- red pseudocolor -RRB-	20352
anti-GFAP	20352
red pseudocolor	20363
cavities 28 d after transplantation of GFP + OB OECs directly -LRB- A -RRB- and rostrocaudally -LRB- B -RRB- or GFP + LP OECs directly -LRB- C -RRB-	20384
cavities 28 d after transplantation of GFP + OB OECs directly -LRB- A -RRB- and rostrocaudally -LRB- B -RRB- or GFP + LP OECs directly	20384
cavities	20384
transplantation of GFP + OB OECs directly -LRB- A -RRB- and rostrocaudally -LRB- B -RRB- or GFP + LP OECs	20404
transplantation of GFP + OB OECs directly -LRB- A -RRB-	20404
transplantation	20404
GFP + OB OECs directly -LRB- A -RRB-	20423
GFP + OB OECs directly	20423
GFP + OB OECs	20423
A	20446
-LRB- B -RRB- or GFP + LP OECs	20468
-LRB- B -RRB-	20468
GFP + LP OECs	20475
C	20498
D	20521
A , Exemplar of quantitation to assess lesion site area -LRB- white line -RRB- and cavity formation	20525
Exemplar	20528
quantitation	20540
lesion site area -LRB- white line -RRB- and cavity	20563
lesion site area	20563
white line	20581
cavity	20597
yellow line	20615
E , Area of the lesion site	20629
E	20629
Area of the lesion site	20632
Area	20632
the lesion site	20640
direct OB-treated rats	20686
all other groups -LRB- n = 4 ; p ≤ 0.05 -RRB-	20723
all other groups	20723
n = 4 ; p ≤ 0.05	20741
n	20741
= 4 ; p ≤ 0.05	20742
= 4	20742
p ≤ 0.05	20746
p	20746
≤ 0.05	20747
F , The area of cavity formed in direct OB	20755
F	20755
The area of cavity formed in direct OB	20758
The area	20758
cavity formed in direct OB	20770
cavity	20770
direct OB	20787
LP	20827
direct and LP R/C rats -LRB- n = 4 ; p ≤ 0.05 and p ≤ 0.05 -RRB-	20830
direct and LP R/C rats	20830
n = 4 ; p ≤ 0.05 and p ≤ 0.05	20854
n = 4 ; p ≤ 0.05	20854
n = 4	20854
n	20854
4	20858
p ≤ 0.05	20861
p	20861
0.05	20865
p ≤ 0.05	20874
p	20874
≤ 0.05	20876
The area of cavity	20885
The area	20885
cavity	20897
rostrocaudal transplantation	20920
R/C LP OEC transplantation significantly reducing cavity formation compared with all groups -LRB- n = 4 ; p ≤ 0.05 -RRB-	20955
R/C LP OEC transplantation	20955
cavity formation compared with all groups -LRB- n = 4 ; p ≤ 0.05 -RRB-	21005
cavity formation	21005
all groups -LRB- n = 4 ; p ≤ 0.05 -RRB-	21036
all groups	21036
n = 4 ; p ≤ 0.05	21048
n	21048
= 4 ; p ≤ 0.05	21049
= 4	21049
p ≤ 0.05	21053
p	21053
≤ 0.05	21054
G , R/C LP OEC rats	21063
the smallest percentage of the lesion site with cavity	21092
the smallest percentage	21092
the lesion site with cavity	21119
the lesion site	21119
cavity	21140
n	21148
= 4 ; p ≤ 0.05	21150
= 4	21150
p ≤ 0.05	21155
p	21155
≤ 0.05	21158
Astrogliosis as measured by GFAP intensity in a defined area around the lesion site	21167
Astrogliosis	21167
GFAP intensity	21195
a defined area around the lesion site	21213
a defined area	21213
the lesion site	21235
GFAP	21265
the contralateral side	21273
significantly decreased reactivity	21302
the lesion site in rostrocaudally -LRB- B , D -RRB- versus directly -LRB- A , C -RRB-	21340
the lesion site in rostrocaudally -LRB- B , D -RRB-	21340
the lesion site	21340
B , D	21375
B	21375
D	21378
directly -LRB- A , C -RRB-	21388
directly	21388
A , C	21398
A	21398
C	21401
transplanted rats compared with control rats	21404
transplanted rats	21404
control rats	21436
rostrocaudal LP OEC transplantation	21463
an additional significant reduction in GFAP intensity	21510
an additional significant reduction	21510
GFAP intensity	21549
rostrocaudal OB OEC transplantation -LRB- n = 4 for all groups except LP direct , n = 5 ; * p ≤ 0.001 , ** p ≤ 0.05 , *** p ≤ 0.01 -RRB-	21578
rostrocaudal OB OEC transplantation	21578
n = 4 for all groups except LP direct , n = 5 ; * p ≤ 0.001 , ** p ≤ 0.05 , *** p ≤ 0.01	21615
n	21615
= 4 for all groups except LP direct , n = 5 ; * p ≤ 0.001 , ** p ≤ 0.05 , *** p ≤ 0.01	21616
4	21617
all groups except LP direct , n = 5 ; * p ≤ 0.001 , **	21623
all groups	21623
LP	21641
n = 5	21652
n	21652
5	21654
p	21658
≤ 0.001	21659
p ≤ 0.05	21669
p	21669
0.05	21671
*** p ≤ 0.01	21677
*** p	21677
≤ 0.01	21681
Data	21689
mean ± SEM	21711
Scale bars , 250µm .	21722
Scale bars	21722
250µm	21734
Figure 4 .	21742
Figure	21742
4	21749
OEC interactions with endogenous glia	21752
OEC interactions	21752
endogenous glia	21774
LP and OB OECs	21791
Schwann cell infiltration	21814
Rat-specific p75 positive -LRB- red -RRB- endogenous Schwann cells infiltrate the lesion site in LP-treated -LRB- A -RRB- and OB-treated -LRB- C -RRB- rats , associating closely with both LP OECs -LRB- B , arrow -RRB- and OB OECs -LRB- D , arrow -RRB- , as well as with astrocytes -LRB- GFAP ; blue , arrowhead -RRB- .	21841
Rat-specific p75 positive -LRB- red -RRB-	21841
Rat-specific p75	21841
endogenous Schwann cells	21873
the lesion site in LP-treated -LRB- A -RRB- and OB-treated -LRB- C -RRB- rats	21909
the lesion site	21909
LP-treated -LRB- A -RRB- and OB-treated -LRB- C -RRB- rats	21928
A	21940
C	21960
both LP OECs -LRB- B , arrow -RRB- and OB OECs -LRB- D , arrow -RRB-	21994
both LP OECs -LRB- B , arrow -RRB- and OB OECs	21994
LP OECs -LRB- B , arrow -RRB-	21999
LP OECs	21999
B , arrow	22008
B	22008
arrow	22011
OB OECs	22022
astrocytes -LRB- GFAP ; blue , arrowhead -RRB-	22058
astrocytes	22058
GFAP ; blue , arrowhead	22070
GFAP	22070
blue , arrowhead	22076
blue	22076
arrowhead	22082
Scale bars , 250µm .	22094
Scale bars	22094
250µm	22106
Figure 5 .	22114
Figure	22114
5	22121
Neurofilament-positive axon sprouting into the lesion site	22124
Neurofilament-positive axon	22124
the lesion site	22167
rostrocaudal LP OEC transplantation	22205
OB R/C transplantation -LRB- C -RRB-	22242
OB R/C transplantation	22242
C	22266
fewer NF-positive axons sprouting into the lesion site -LRB- arrowhead -RRB- compared with OB direct -LRB- D -RRB- , LP R/C -LRB- A -RRB- or direct -LRB- B -RRB- transplantation	22280
fewer NF-positive axons	22280
the lesion site -LRB- arrowhead -RRB-	22319
the lesion site	22319
arrowhead	22336
OB direct -LRB- D -RRB- , LP R/C -LRB- A -RRB- or direct -LRB- B -RRB- transplantation	22361
OB direct -LRB- D -RRB-	22361
OB direct	22361
D	22372
LP R/C -LRB- A -RRB-	22376
LP R/C	22376
A	22384
direct -LRB- B -RRB- transplantation	22390
B	22398
E , Fluorescence densitometry for NF-positive pixels within the lesion site , as determined by outlining the GFAP-reactive border ,	22418
E	22418
Fluorescence densitometry for NF-positive pixels within the lesion site , as determined by outlining the GFAP-reactive border	22421
Fluorescence densitometry	22421
NF-positive pixels within the lesion site , as determined by outlining the GFAP-reactive border	22451
NF-positive pixels	22451
the lesion site , as determined by outlining the GFAP-reactive border	22477
the lesion site	22477
the GFAP-reactive border	22521
significantly greater NF-positive reactivity	22555
the lesion site in all treated groups compared with control groups -LRB- p ≤ 0.01 , all groups -RRB-	22607
the lesion site	22607
all treated groups compared with control groups -LRB- p ≤ 0.01 , all groups -RRB-	22626
all treated groups	22626
control groups -LRB- p ≤ 0.01 , all groups -RRB-	22659
control groups	22659
p ≤	22676
0.01 , all groups	22678
0.01	22678
all groups	22684
Reactivity	22697
LP R/C transplanted rats compared with LP direct and OB R/C and OB direct rats -LRB- n = 4 , 5 , 4 , 4 ; p ≤ 0.001 all groups -RRB-	22742
LP R/C transplanted rats	22742
LP direct and OB R/C and OB direct rats -LRB- n = 4 , 5 , 4 , 4 ; p ≤ 0.001 all groups -RRB-	22781
LP direct	22781
OB R/C and OB direct rats -LRB- n = 4 , 5 , 4 , 4 ; p ≤ 0.001 all groups -RRB-	22795
OB R/C and OB	22795
direct rats -LRB- n = 4 , 5 , 4 , 4 ; p ≤ 0.001 all groups -RRB-	22809
direct rats	22809
n = 4 , 5 , 4 , 4 ; p ≤ 0.001 all groups	22822
n = 4	22822
n	22822
4	22824
5 , 4	22827
5	22827
4	22830
4 ; p ≤ 0.001 all groups	22833
4	22833
p ≤ 0.001 all groups	22836
p	22836
≤ 0.001 all groups	22837
OB OEC transplanted rats	22874
OB OEC	22874
rats	22894
there	22900
significantly greater NF-positive pixels in the lesion site in direct versus R/C rats -LRB- n04 ; p ≤ 0.05 -RRB-	22910
significantly greater NF-positive pixels	22910
the lesion site in direct versus R/C rats -LRB- n04 ; p ≤ 0.05 -RRB-	22954
the lesion site	22954
direct versus R/C rats -LRB- n04 ; p ≤ 0.05 -RRB-	22973
direct	22973
R/C rats -LRB- n04 ; p ≤ 0.05 -RRB-	22987
R/C rats	22987
n04 ; p ≤ 0.05	22997
n04	22997
p ≤ 0.05	23002
p	23002
≤ 0.05	23003
Data	23011
mean ± SEM	23033
Scale bars , 100µm .	23044
Scale bars	23044
100µm	23056
Figure 6 .	23064
Figure	23064
6	23071
LP and OB OECs	23074
directional angiogenesis	23097
Angiogenesis , as recognized by anti-RECA immunoreaction -LRB- red -RRB- ,	23123
Angiogenesis	23123
anti-RECA immunoreaction -LRB- red -RRB-	23154
anti-RECA immunoreaction	23154
red	23180
the lesion site -LRB- arrowhead -RRB- in OB direct -LRB- B -RRB- and R/C -LRB- C -RRB- and LP direct -LRB- D -RRB- and R/C -LRB- E -RRB- rats	23200
the lesion site -LRB- arrowhead -RRB- in OB direct -LRB- B -RRB- and R/C -LRB- C -RRB- and LP direct -LRB- D -RRB-	23200
the lesion site -LRB- arrowhead -RRB-	23200
the lesion site	23200
arrowhead	23217
OB direct -LRB- B -RRB- and R/C -LRB- C -RRB- and LP direct -LRB- D -RRB-	23231
OB direct -LRB- B -RRB-	23231
OB direct	23231
B	23242
R/C -LRB- C -RRB-	23249
R/C	23249
C	23254
LP direct -LRB- D -RRB-	23261
LP direct	23261
D	23272
R/C -LRB- E -RRB- rats	23279
R/C	23279
E	23284
rats	23287
F , Directionality	23293
F	23293
Directionality	23296
best-fit lines	23340
RECA-positive structures	23358
normal distributions	23397
each intersection point	23421
a contour map of intersection points	23458
a contour map	23458
intersection points	23475
Contour	23496
control -LRB- G -RRB- , OB direct -LRB- H -RRB- , OB R/C -LRB- I -RRB- , LP direct -LRB- J -RRB- , and LP R/C -LRB- K -RRB-	23513
control -LRB- G -RRB- , OB direct -LRB- H -RRB- , OB R/C -LRB- I -RRB- , LP direct -LRB- J -RRB- , and LP R/C	23513
control -LRB- G -RRB-	23513
control	23513
G	23522
OB direct -LRB- H -RRB-	23526
OB direct	23526
H	23537
OB R/C -LRB- I -RRB-	23541
OB R/C	23541
I	23549
LP direct -LRB- J -RRB-	23554
LP direct	23554
J	23565
LP R/C	23574
K	23582
the number of intersections in a given area	23591
the number	23591
intersections in a given area	23605
intersections	23605
a given area	23622
the color scale bar	23652
The height of the contour map in G -- K falling within the lesion site -LRB- white outlines in G -- K -RRB- , as indicated by anti-GFAP -LRB- green pseudocolor -RRB- ,	23673
The height	23673
the contour map in G -- K falling within the lesion site -LRB- white outlines in G -- K -RRB-	23687
the contour map in G	23687
the contour map	23687
G	23706
K falling within the lesion site -LRB- white outlines in G -- K -RRB-	23708
K falling	23708
the lesion site	23725
white	23742
G -- K	23760
G	23760
K	23762
anti-GFAP -LRB- green pseudocolor -RRB-	23782
anti-GFAP	23782
green pseudocolor	23793
the height falling within the same area randomly placed 100 times throughout the image to produce a directionality quotient	23831
the height	23831
the same area randomly placed 100 times throughout the image to produce a directionality quotient	23857
the same area	23857
100 times	23887
the image to produce a directionality quotient	23908
a directionality quotient	23929
Directionality quotients and total number of blood vessels	23956
Directionality quotients	23956
total number of blood vessels	23985
total number	23985
blood vessels	24001
tissue area	24031
Table 1	24061
Scale bars , 250µm .	24070
Scale bars	24070
250µm	24082
Figure 7 .	24090
Figure	24090
7	24097
Autotomy	24100
OB OEC transplantation	24123
LP OEC transplantation	24162
A , Schematic of scoring system for autotomy ; from left to right , scores would be	24186
Schematic of scoring system for autotomy	24189
Schematic	24189
scoring system for autotomy	24202
scoring system	24202
autotomy	24221
scores	24251
1 , 2 , and 3 , respectively	24279
1 , 2 , and 3	24279
B , Direct LP	24306
OEC-treated rats show significantly greater autotomy than direct OB OEC-transplanted rats and control rats	24319
OEC-treated rats	24319
significantly greater autotomy	24341
direct OB OEC-transplanted rats and control rats	24377
n	24427
= 5 , 4 , 5	24428
= 5	24428
4	24432
5	24435
p ≤ 0.01 , *** p	24439
p	24439
≤ 0.01 , *** p	24440
≤ 0.01	24440
*** p	24447
0.05	24452
R/C LP OEC rats	24459
significantly increased autotomy	24483
R/C OB OEC-transplanted rats -LRB- n = 4 , 4 ; ** p ≤ 0.05 -RRB-	24530
R/C OB OEC-transplanted rats	24530
n	24560
= 4 , 4	24561
= 4	24561
p	24570
≤ 0.05	24571
they	24583
control rats	24621
R/C OB rats	24635
significantly decreased autotomy	24654
control rats -LRB- p ≤ 0.05 -RRB-	24701
control rats	24701
p ≤ 0.05	24716
p	24716
≤ 0.05	24717
Data	24725
mean ± SEM	24747
Figure 8 .	24759
Figure	24759
8	24766
TH-positive and subP-positive axons	24769
LP and OB OEC transplantation	24838
subP axons	24869
response	24895
LP OEC -LRB- A -RRB-	24907
LP OEC	24907
A	24915
than to OB OEC -LRB- B -RRB- transplantation	24918
OB OEC -LRB- B -RRB-	24926
OB OEC	24926
B	24934
C , Quantification of subP-positive pixels by fluorescence densitometry	24954
C	24954
Quantification of subP-positive pixels by fluorescence densitometry	24957
Quantification	24957
subP-positive pixels by fluorescence densitometry	24975
subP-positive pixels	24975
fluorescence densitometry	24999
increased subP in OB OEC animals 1	25045
increased subP in OB OEC animals	25045
increased subP	25045
OB OEC animals	25063
1	25078
0.5 mmrostral and caudal	25084
0.5 mmrostral	25084
caudal	25101
the lesion site	25111
the lesion site compared with LP-treated rats	25138
the lesion site	25138
LP-treated rats	25168
n = 9 , 8 ; p ≤ 0.05 , all groups	25185
n = 9	25185
n	25185
9	25187
8 ; p ≤ 0.05	25190
8	25190
p ≤ 0.05	25193
p	25193
0.05	25195
all groups	25201
all	25201
groups	25205
CGRP-positive axons	25214
response to LP -LRB- D -RRB- and OB -LRB- E -RRB- OEC transplantation	25244
response to LP -LRB- D -RRB-	25244
response	25244
LP -LRB- D -RRB-	25256
LP	25256
D	25260
OB -LRB- E -RRB- OEC transplantation	25267
OB	25267
E	25271
OEC transplantation	25274
control groups -LRB- p ≤ 0.001 -RRB-	25308
control groups	25308
p ≤ 0.001	25325
p	25325
≤ 0.001	25326
0.5 mm rostral to the lesion in LP than OB rats -LRB- n = 9 , 8 ; p ≤ 0.05 -RRB- -LRB- F -RRB-	25364
0.5 mm rostral	25364
the lesion in LP than OB rats -LRB- n = 9 , 8 ; p ≤ 0.05 -RRB- -LRB- F -RRB-	25382
the lesion	25382
LP than OB rats -LRB- n = 9 , 8 ; p ≤ 0.05 -RRB- -LRB- F -RRB-	25396
LP	25396
OB rats -LRB- n = 9 , 8 ; p ≤ 0.05 -RRB- -LRB- F -RRB-	25404
OB rats -LRB- n = 9 , 8 ; p ≤ 0.05 -RRB-	25404
OB rats	25404
n = 9 , 8 ; p ≤ 0.05	25413
n	25413
= 9 , 8 ; p ≤ 0.05	25414
= 9 , 8	25414
= 9	25414
8	25418
p ≤ 0.05	25421
p	25421
≤ 0.05	25422
F	25430
The quantity and distribution of sprouting 5-HT-positive axons in LP -LRB- G -RRB- and OB -LRB- H -RRB-	25435
The quantity and distribution	25435
5-HT-positive axons	25478
LP -LRB- G -RRB- and OB -LRB- H -RRB-	25501
LP	25501
G	25505
OB	25512
H	25516
OEC-treated rats	25519
robust growth rostral to and within the lesion site -LRB- I -RRB- compared with control animals -LRB- p ≤ 0.05 -RRB-	25553
robust growth rostral to and within the lesion site -LRB- I -RRB-	25553
robust growth rostral	25553
the lesion site	25589
I	25606
control animals	25624
p ≤ 0.05	25642
p	25642
≤ 0.05	25643
few axons	25656
the lesion -LRB- G , H , insets -RRB-	25686
the lesion	25686
G , H , insets	25698
G	25698
H	25701
insets	25704
TH axons	25713
LP OEC -LRB- J -RRB-	25738
LP OEC	25738
J	25746
OB OEC -LRB- K -RRB- transplantation	25758
K	25766
L , TH growth , quantified by immunofluorescence densitometry ,	25787
L	25787
TH growth	25790
immunofluorescence densitometry	25815
LP OEC-treated rats 1 and 0.5 mmrostral to and within the lesion site	25878
LP OEC-treated rats 1	25878
LP OEC-treated rats	25878
1	25898
0.5 mmrostral to and within the lesion site	25904
0.5 mmrostral	25904
the lesion site	25931
the same sites in OB OEC-treated rats and control rats -LRB- K , inset -RRB- -LRB- n = 9 , 8 , 8 ; p ≤ 0.001 and p ≤ 0.001 -RRB-	25972
the same sites	25972
OB OEC-treated rats and control rats -LRB- K , inset -RRB-	25990
OB OEC-treated rats	25990
control rats -LRB- K , inset -RRB-	26014
control rats	26014
K , inset	26028
K	26028
n = 9 , 8 , 8 ; p ≤ 0.001 and p ≤ 0.001	26039
n = 9	26039
n	26039
9	26041
8 , 8 ; p ≤ 0.001	26044
8 , 8	26044
8	26044
8	26047
p ≤ 0.001	26050
p	26050
≤ 0.001	26051
p ≤ 0.001	26062
p	26062
≤ 0.001	26063
All axons	26072
Data	26093
mean ± SEM	26115
Scale bars , 100µm .	26126
Scale bars	26126
100µm	26138
their comparative ability	26156
regeneration	26193
OECs	26207
the LP or OB of postnatal day 5 mice homozygous for eGFP	26231
the LP or OB	26231
postnatal day 5 mice homozygous for eGFP	26247
postnatal day	26247
5 mice	26261
eGFP	26283
the betta-actin promoter -LRB- Ramon - Cueto and Nieto-Sampedro , 1994 ; Au and Roskams , 2003 -RRB-	26294
the betta-actin promoter	26294
Ramon	26320
Cueto and Nieto-Sampedro , 1994 ; Au and Roskams , 2003	26327
Cueto and Nieto-Sampedro	26327
1994 ; Au and Roskams	26353
1994	26353
Au and Roskams	26359
2003	26375
LP -LRB- Fig. 1A , C -RRB- and OB -LRB- Fig. 1B , D -RRB- OECs grown for 14 DIV	26382
LP -LRB- Fig. 1A , C -RRB- and OB -LRB- Fig. 1B , D -RRB- OECs	26382
LP -LRB- Fig. 1A , C -RRB-	26382
LP	26382
Fig. 1A , C	26386
Fig. 1A	26386
C	26394
OB -LRB- Fig. 1B , D -RRB- OECs	26401
OB	26401
Fig. 1B , D	26405
Fig. 1B	26405
D	26413
OECs	26416
14 DIV	26431
similar morphologic and antigenic profiles	26451
S100betta , GFAP , and the p75 neurotrophin receptor	26498
S100betta	26498
GFAP	26509
the p75 neurotrophin receptor	26519
LP and OB OECs	26550
and fusiform morphologies -LRB- Fig. 1A , B -RRB-	26590
fusiform morphologies -LRB- Fig. 1A , B -RRB-	26594
fusiform morphologies	26594
Fig. 1A , B	26617
Fig. 1A	26617
B	26625
OB OECs	26629
a broader range of p75 expression	26650
a broader range	26650
p75 expression	26669
LP OECs	26689
some OB OECs	26698
highly p75 positive , whereas the majority demonstrated low p75 levels -LRB- Fig. 1B -RRB-	26716
highly p75 positive	26716
the majority	26745
low p75 levels -LRB- Fig. 1B -RRB-	26771
low p75 levels	26771
Fig. 1B	26787
their antigenic similarity	26805
LP OECs	26833
a threefold higher expansion rate than OB OECs	26854
a threefold higher expansion rate	26854
OB OECs	26893
passage 1	26906
2 under the same culture conditions	26916
2	26916
the same culture conditions	26924
passage 2 eGFP + LP and OB OECs cultured for 14 DIV	26962
passage 2 eGFP	26962
LP and OB OECs cultured for 14 DIV	26978
LP and OB OECs	26978
14 DIV	27006
or at sites 1mmrostral and caudal	27052
or at sites	27052
a crush of the dorsolateral funiculus	27089
a crush	27089
the dorsolateral funiculus	27100
We	27128
differences between LP and OB OECs that may be predicted based on their home environments	27147
differences	27147
LP and OB OECs	27167
their home environments	27213
the PNS and CNS compartments of the olfactory system such as their ability to migrate within the CNS and preferential interactions with endogenous glia	27240
the PNS and CNS compartments	27240
the olfactory system such as their ability to migrate within the CNS and preferential interactions with endogenous glia	27272
the olfactory system	27272
their ability to migrate within the CNS and preferential interactions with endogenous glia	27301
the CNS and preferential interactions	27333
the CNS	27333
preferential interactions	27345
endogenous glia	27376
We	27393
R/C-transplanted LP and OB OECs	27411
different patterns of migration within the CNS	27453
different patterns	27453
migration within the CNS	27475
migration	27475
the CNS	27492
their change	27513
distribution from 24 h	27529
distribution	27529
24 h	27547
28 d after lesion -LRB- Fig. 2 -RRB-	27555
28 d	27555
lesion -LRB- Fig. 2 -RRB-	27566
lesion	27566
Fig. 2	27574
24 h after injection	27586
24 h	27586
injection	27597
25 ± 7.7 % of all transplanted LP OECs and 30 ± 6.9 % of OB OECs	27608
25	27608
± 7.7 % of all transplanted LP OECs and 30	27611
± 7.7 %	27611
7.7 %	27613
all transplanted LP OECs and 30	27621
all transplanted LP OECs	27621
30	27650
6.9 %	27653
OB OECs	27661
the lesion site	27691
both types of OECs	27712
both types	27712
OECs	27726
a stream from the rostral injection point	27758
a stream	27758
the rostral injection point	27772
lesion center	27803
we	27826
cells	27846
the caudal injection point -LRB- which retained 42 ± 10.6 % of total LP-OECs and 28 ± 6.2 % OB OECs transplanted -RRB- and lesion site	27860
the caudal injection point -LRB- which retained 42 ± 10.6 % of total LP-OECs and 28 ± 6.2 % OB OECs transplanted -RRB-	27860
the caudal injection point	27860
42 ± 10.6 %	27903
42	27903
10.6 %	27906
total LP-OECs and 28 ± 6.2 %	27915
total LP-OECs	27915
28 ± 6.2 %	27933
28	27933
6.2 %	27936
OB OECs	27941
lesion site	27967
four of five LP and three of four OB-transplanted rats	27983
four of five LP	27983
four	27983
five LP	27991
three of four OB-transplanted rats	28003
three	28003
four OB-transplanted rats	28012
this	28040
fluid pressure	28059
a subset of OECs from their rostral but not their caudal injection point	28097
a subset of OECs from their rostral	28097
a subset	28097
OECs from their rostral	28109
OECs	28109
their rostral	28119
their caudal injection point	28141
Migration of GFP + OECs from the caudal injection point to the lesion site	28171
Migration	28171
GFP + OECs from the caudal injection point to the lesion site	28184
GFP + OECs	28184
the caudal injection point to the lesion site	28199
the caudal injection point	28199
the lesion site	28229
28 d in LP - and OB-transplanted rats	28260
28 d	28260
LP - and OB-transplanted rats	28268
GFP + OECs -LRB- three of four LP and four of four OB -RRB- -LRB- Fig. 2A , B -RRB-	28312
GFP + OECs -LRB- three of four LP and four of four OB -RRB-	28312
GFP + OECs	28312
three of four LP and four of four OB	28323
three of four LP	28323
three	28323
four LP	28332
four of four OB	28344
four	28344
four OB	28352
Fig. 2A , B	28362
Fig. 2A	28362
B	28370
the frequency and distribution of OECs between the injection and the lesion sites	28383
the frequency and distribution	28383
OECs between the injection and the lesion sites	28417
OECs	28417
the injection and the lesion sites	28430
the injection	28430
the lesion sites	28448
OEC types	28496
n = 3 , 4 ; p ≤ 0.05	28507
n	28507
= 3 , 4 ; p ≤ 0.05	28509
= 3 , 4	28509
= 3	28509
4	28514
p ≤ 0.05	28517
p	28517
≤ 0.05	28519
transplanted rats	28543
more GFP + OECs at 28 d	28565
more GFP	28565
more	28565
GFP	28570
OECs at 28 d	28575
OECs	28575
28 d	28583
directly transplanted rats -LRB- 0 of 5 LP OECs ; one of four OB OECs -RRB-	28593
directly transplanted rats	28593
0 of 5 LP OECs ; one of four OB OECs	28621
0	28621
5 LP OECs ; one of four OB OECs	28626
5 LP OECs	28626
one of four OB OECs	28637
one	28637
four OB OECs	28644
GFP + OEC distribution	28674
GFP	28674
OEC distribution	28679
≈ 45 % of surviving GFP + OB OECs in rostrocaudally transplanted rats	28696
≈ 45 %	28696
45 %	28697
GFP + OB OECs in rostrocaudally transplanted rats	28714
GFP + OB OECs	28714
rostrocaudally transplanted rats	28730
the caudal injection point and lesion site -LRB- n = 4 -RRB- -LRB- Fig. 2D -RRB- , similar to the distribution of LP OECs 7 d after injury and rostrocaudal transplantation -LRB- Fig. 3C -RRB-	28788
the caudal injection point and lesion site -LRB- n = 4 -RRB- -LRB- Fig. 2D -RRB-	28788
the caudal injection point and lesion site -LRB- n = 4 -RRB-	28788
the caudal injection point and lesion site	28788
n	28832
4	28836
Fig. 2D	28840
similar to the distribution of LP OECs 7 d after injury	28850
similar to the distribution of LP OECs	28850
the distribution of LP	28861
the distribution	28861
LP	28881
injury	28899
rostrocaudal transplantation -LRB- Fig. 3C -RRB-	28910
rostrocaudal transplantation	28910
Fig. 3C	28940
contrast	28953
28 d	28966
only ≈ 6 % of surviving LP OECs	28972
only ≈ 6 %	28972
surviving LP OECs	28984
the caudal injection point -LRB- Fig. 2A -RRB-	29016
the caudal injection point	29016
Fig. 2A	29044
51 % of surviving GFP + cells found within the lesion site	29059
51 %	29059
GFP + cells found within the lesion site	29076
GFP + cells	29076
the lesion site	29100
migratory differences in vivo	29144
migratory differences	29144
vivo	29169
intrinsic differences	29186
migratory ability of LP and OB OECs	29211
migratory ability	29211
LP and OB OECs	29232
a Boyden chamber assay	29248
Cells plated onto a porousmembranecoated with poly-L-lysine -LRB- normal OEC substrate -RRB- or laminin -LRB- rich at the lesion site -RRB- -LRB- Ramer et al. , 2004b -RRB-	29281
Cells	29281
a porousmembranecoated with poly-L-lysine -LRB- normal OEC substrate -RRB- or laminin -LRB- rich at the lesion site -RRB-	29299
a	29299
poly-L-lysine -LRB- normal OEC substrate -RRB- or laminin -LRB- rich at the lesion site -RRB-	29327
poly-L-lysine	29327
normal OEC substrate	29342
laminin	29367
the lesion site	29384
Ramer	29402
et al. , 2004b	29408
et al.	29408
2004b	29416
the membrane	29465
the ratios of migratory versus nonmigratory cells	29483
the ratios	29483
migratory versus nonmigratory cells	29497
migratory	29497
nonmigratory cells	29514
20 h	29550
a significantly greater number of LP OECs	29556
a significantly greater number	29556
LP OECs	29590
thanOBOECs	29607
PLL -LRB- n = 3 ; p ≤ 0.02 -RRB-	29621
PLL	29621
n = 3 ; p ≤ 0.02	29626
n	29626
= 3 ; p ≤ 0.02	29628
= 3	29628
p ≤ 0.02	29633
p	29633
≤ 0.02	29635
this effect	29648
laminin -LRB- n = 3 ; p ≤ 0.02 -RRB- , in which 85 % fewer OB OECs migrated -LRB- Fig. 2E -RRB-	29677
laminin -LRB- n = 3 ; p ≤ 0.02 -RRB-	29677
laminin	29677
n = 3 ; p ≤ 0.02	29686
n	29686
= 3 ; p ≤ 0.02	29688
= 3	29688
p ≤ 0.02	29693
p	29693
≤ 0.02	29695
85 % fewer OB OECs	29713
85 %	29713
Fig. 2E	29741
These data	29751
vivo	29779
LP OECs	29798
OB OECs	29832
Lesion site area and cavity formation are decreased by LP versus OB OEC transplantation Differences in migratory ability	29841
Lesion site area and cavity formation	29841
LP versus OB OEC transplantation Differences	29896
LP	29896
OB OEC transplantation Differences	29906
migratory ability	29944
LP and OB OECs	29989
lesion and cavity formation	30025
the acute phase of SCI	30060
the acute phase	30060
SCI	30079
differential migration	30100
lesion size	30139
we	30152
the GFAPreactive border	30160
a marker of the perimeter of the lesion area	30187
a marker	30187
the perimeter of the lesion area	30199
the perimeter	30199
the lesion area	30216
lesion area , cavity area , and the percentage of the lesion site occupied by cavity -LRB- Fig. 3A -RRB-	30245
lesion area	30245
cavity area	30258
the percentage of the lesion site occupied by cavity -LRB- Fig. 3A -RRB-	30275
the percentage	30275
the lesion site	30293
cavity -LRB- Fig. 3A -RRB-	30321
cavity	30321
Fig. 3A	30329
All groups	30339
an easily defined lesion area containing some evidence of a cavity	30360
an easily defined lesion area	30360
some evidence of a cavity	30401
some evidence	30401
a cavity	30418
rats that received directOBOEC transplants -LRB- Fig. 3A -RRB-	30437
rats	30437
directOBOEC transplants -LRB- Fig. 3A -RRB-	30456
directOBOEC transplants	30456
Fig. 3A	30481
a significantly increased lesion	30494
site area -LRB- by approximately twofold to threefold -RRB- compared with rats that received the same cells rostrocaudally -LRB- Fig. 3B -RRB- or with rats that received LP OECs transplanted either directly -LRB- Fig. 3C -RRB- or rostrocaudally -LRB- n = 4 all groups ; p ≤ 0.02 -RRB-	30527
site area -LRB- by approximately twofold to threefold -RRB- compared with rats that received the same cells rostrocaudally -LRB- Fig. 3B -RRB- or with rats that received LP OECs transplanted either directly -LRB- Fig. 3C -RRB- or rostrocaudally	30527
site area -LRB- by approximately twofold to threefold -RRB-	30527
site area	30527
rats that received the same cells rostrocaudally -LRB- Fig. 3B -RRB-	30591
rats	30591
the same cells	30610
Fig. 3B	30641
rats that received LP OECs transplanted either directly -LRB- Fig. 3C -RRB- or rostrocaudally	30658
rats	30658
LP OECs transplanted either directly -LRB- Fig. 3C -RRB- or rostrocaudally	30677
LP OECs transplanted either directly -LRB- Fig. 3C -RRB-	30677
LP OECs transplanted either directly	30677
LP OECs	30677
Fig. 3C	30715
n = 4 all groups ; p ≤ 0.02	30743
n	30743
= 4 all groups ; p ≤ 0.02	30745
= 4 all groups	30745
= 4	30745
all groups	30749
p ≤ 0.02	30761
p	30761
≤ 0.02	30763
Fig. 3D	30772
Rats that received direct or rostrocaudally transplanted LP OECs	30782
Rats that received direct	30782
Rats	30782
rostrocaudally transplanted LP OECs	30811
smaller cavities	30862
rats	30884
direct OB OEC transplants -LRB- n 5 , 4 , 4 ; p ≤ 0.02 and 0.04 , respectively -RRB- -LRB- Fig. 3F -RRB-	30894
direct OB OEC transplants -LRB- n 5 , 4 , 4 ; p ≤ 0.02 and 0.04 , respectively -RRB-	30894
direct OB OEC transplants	30894
n 5 , 4	30921
n 5	30921
4	30926
4 ; p ≤ 0.02 and 0.04 , respectively	30929
4	30929
p ≤ 0.02 and 0.04 , respectively	30932
p ≤	30932
0.02 and 0.04	30936
Fig. 3F	30966
The greatest significant decrease in cavity formation	30976
The greatest significant decrease	30976
cavity formation	31013
rats that received LP OECs transplanted rostrocaudally -LRB- Fig. 3F -RRB- , which also resulted in a significantly lower percentage of the lesion site occupied by cavity -LRB- Fig. 3G -RRB- , a trend not observed after rostrocaudal OB OEC transplantation -LRB- Fig. 3G -RRB-	31037
rats that received LP OECs transplanted rostrocaudally -LRB- Fig. 3F -RRB-	31037
rats	31037
LP OECs transplanted rostrocaudally	31056
LP OECs	31056
Fig. 3F	31093
a significantly lower percentage of the lesion site occupied by cavity -LRB- Fig. 3G -RRB- , a trend not observed after rostrocaudal OB OEC transplantation -LRB- Fig. 3G -RRB-	31126
a significantly lower percentage	31126
the lesion site occupied by cavity -LRB- Fig. 3G -RRB- , a trend not observed after rostrocaudal OB OEC transplantation	31162
the lesion site	31162
cavity -LRB- Fig. 3G -RRB- , a trend not observed after rostrocaudal OB OEC transplantation	31190
cavity -LRB- Fig. 3G -RRB-	31190
cavity	31190
Fig. 3G	31198
a trend	31208
rostrocaudal OB OEC transplantation	31235
Fig. 3G	31272
The smaller lesion site area in rostrocaudally transplanted LP and OB OEC rats and directly transplanted LP OEC rats was four times smaller than that seen in control animals , which also developed cavities an average of 46 times larger -LRB- p ≤ 0.01 , all groups -RRB- than transplanted rats , occupying 93 ± 3.3 % of the lesion site .	31282
The smaller lesion site area in rostrocaudally	31282
The smaller lesion site area	31282
transplanted LP and OB OEC rats and directly transplanted LP OEC rats	31329
transplanted LP and OB OEC rats	31329
transplanted LP	31329
OB OEC rats	31349
directly transplanted LP OEC rats	31365
four times	31403
that seen in control animals , which also developed cavities an average of 46 times larger -LRB- p ≤ 0.01 , all groups -RRB- than transplanted rats	31427
that	31427
control animals , which also developed cavities an average of 46 times larger -LRB- p ≤ 0.01 , all groups -RRB- than transplanted rats	31440
control animals	31440
cavities an average of 46 times larger -LRB- p ≤ 0.01 , all groups -RRB-	31478
cavities	31478
an average	31487
46 times larger -LRB- p ≤ 0.01 , all groups -RRB-	31501
46 times larger	31501
p ≤	31519
0.01 , all groups	31523
0.01	31523
all groups	31529
transplanted rats	31546
93	31575
3.3 %	31580
the lesion site	31588
Reactive astrogliosis	31605
rostrocaudal transplantation The physical barrier of the lesion site and cavity are major obstacles to axonal regeneration -LRB- Schwab , 2002 -RRB-	31641
rostrocaudal transplantation	31641
The physical barrier of the lesion site and cavity	31670
The physical barrier	31670
the lesion site and cavity	31694
major obstacles to axonal regeneration -LRB- Schwab , 2002 -RRB-	31725
major obstacles	31725
axonal regeneration -LRB- Schwab , 2002 -RRB-	31744
axonal regeneration	31744
Schwab	31765
2002	31773
the astro - cytic scar , produced by reactive astrocytes ,	31789
the astro	31789
cytic scar , produced by reactive astrocytes	31800
cytic scar	31800
reactive astrocytes	31824
growthinhibitory molecules that form an additional chemical obstacle to growing axons -LRB- Moreau-Fauvarque et al. , 2003 ; Camand et al. , 2004 -RRB-	31854
growthinhibitory molecules	31854
an additional chemical obstacle	31891
growing axons -LRB- Moreau-Fauvarque et al. , 2003 ; Camand et al. , 2004 -RRB-	31926
growing axons	31926
Moreau-Fauvarque	31941
et al. , 2003 ; Camand et al. , 2004	31958
et al.	31958
2003 ; Camand et al.	31966
2003	31966
Camand et al.	31972
Camand	31972
et al.	31979
2004	31987
both the OEC type and method of introduction	32002
the OEC type	32007
method of introduction	32024
method	32024
introduction	32034
the lesion site and cavity area	32069
we	32102
inhibitory astrogliosis	32123
treatment groups	32182
All groups	32200
the distribution of GFAP-expressing astrocytes -LRB- Fig. 3A -- D -RRB-	32227
the distribution	32227
GFAP-expressing astrocytes -LRB- Fig. 3A -- D -RRB-	32247
GFAP-expressing astrocytes	32247
Fig. 3A -- D	32275
Fig. 3A	32275
D	32283
The intensity of GFAP immunoreactivity surrounding and including the lesion site	32287
The intensity	32287
GFAP immunoreactivity surrounding and including the lesion site	32304
GFAP immunoreactivity	32304
the lesion site	32352
an equally sized defined area of GFAP immunoreactivity contralateral to the lesion site	32386
an equally sized	32386
area of GFAP immunoreactivity contralateral	32411
area	32411
GFAP immunoreactivity contralateral	32419
the lesion site	32458
This	32475
between-animal differences in baseline reactivity and background staining	32495
between-animal differences	32495
baseline reactivity and background staining	32525
baseline reactivity	32525
background staining	32549
Direct transplantation of LP and OB OECs	32570
Direct transplantation	32570
LP and OB OECs	32596
a reactive astrogliosis	32620
extent	32655
injection of media -LRB- Fig. 3A , C , H -RRB-	32672
injection	32672
media -LRB- Fig. 3A , C , H -RRB-	32685
media	32685
Fig. 3A	32692
C	32700
H	32702
contrast	32709
rostrocaudal injection of media	32719
rostrocaudal injection	32719
media	32745
the most extensive astrogliosis of all treatment groups , a reaction that was significantly lowered by transplantation of both OEC types rostral and caudal to the lesion -LRB- n = 4 , 4 , 4 ; LP , p ≤ 0.001 ; OB , p ≤ 0.01 -RRB-	32762
the most extensive astrogliosis	32762
all treatment groups , a reaction that was significantly lowered by transplantation of both OEC types rostral and caudal to the lesion -LRB- n = 4 , 4 , 4 ; LP , p ≤ 0.001 ; OB , p ≤ 0.01 -RRB-	32797
all treatment groups	32797
a reaction that was significantly lowered by transplantation of both OEC types rostral and caudal to the lesion -LRB- n = 4 , 4 , 4 ; LP , p ≤ 0.001 ; OB , p ≤ 0.01 -RRB-	32819
a reaction	32819
transplantation of both OEC types rostral and caudal	32864
transplantation	32864
both OEC types rostral and caudal	32883
both OEC types	32883
both OEC	32883
the lesion -LRB- n = 4 , 4 , 4 ; LP , p ≤ 0.001 ; OB , p ≤ 0.01 -RRB-	32920
the lesion	32920
n = 4 , 4 , 4 ; LP , p ≤ 0.001 ; OB , p ≤ 0.01	32932
n = 4 , 4 , 4 ; LP , p ≤ 0.001 ; OB , p	32932
n = 4	32932
n	32932
4	32936
4 , 4 ; LP , p ≤ 0.001 ; OB , p	32939
4 , 4	32939
4	32939
4	32942
LP , p ≤ 0.001	32945
LP	32945
p ≤ 0.001	32949
p	32949
≤ 0.001	32951
OB , p	32960
OB	32960
p	32964
≤ 0.01	32966
Rostrocaudal transplantation of both LP and OB OECs	32975
Rostrocaudal transplantation	32975
both LP and OB OECs	33007
GFAP intensity	33056
direct transplantation	33085
rostrocaudal LP OEC transplantation lessening GFAP reactivity to the greatest extent -LRB- n 4 , 4 , 5 , 4 , 4 , 4 ; p ≤ 0.05 -RRB- -LRB- Fig. 3H -RRB-	33114
rostrocaudal LP OEC transplantation	33114
GFAP reactivity	33160
the greatest extent -LRB- n 4 , 4 , 5 , 4 , 4 , 4 ; p ≤ 0.05 -RRB- -LRB- Fig. 3H -RRB-	33179
the greatest extent -LRB- n 4 , 4 , 5 , 4 , 4 , 4 ; p ≤ 0.05 -RRB-	33179
the greatest extent	33179
n 4 , 4 , 5 , 4 , 4	33200
n 4	33200
4	33205
5	33208
4	33211
4	33214
4 ; p ≤ 0.05	33217
4	33217
p ≤ 0.05	33220
p	33220
≤ 0.05	33222
Fig. 3H	33231
The reduced astrocytic reaction observed in rostrocaudal versus direct transplanted rats	33241
The reduced astrocytic reaction	33241
rostrocaudal versus direct transplanted rats	33285
rostrocaudal	33285
direct transplanted rats	33305
this method of transplantation	33344
this method	33344
transplantation	33359
a more permissive environment for axon extension -LRB- Lakatos et al. , 2003 -RRB- , although no additional decrease was observed in CSPG expression between treated groups -LRB- data not shown -RRB- over that reported previously -LRB- Ramer et al. , 2004b -RRB-	33386
a more permissive environment	33386
axon extension -LRB- Lakatos et al. , 2003 -RRB- , although no additional decrease was observed in CSPG expression between treated groups -LRB- data not shown -RRB- over that reported previously	33420
axon extension -LRB- Lakatos et al. , 2003 -RRB-	33420
axon extension	33420
Lakatos	33436
et al. , 2003	33444
et al.	33444
2003	33452
no additional decrease	33468
CSPG expression between treated groups -LRB- data not shown -RRB- over that reported previously	33507
CSPG expression between treated groups	33507
CSPG expression	33507
treated groups	33531
data not shown	33547
data	33547
that reported previously	33568
that	33568
Ramer	33594
et al. , 2004b	33600
et al.	33600
2004b	33608
LP and OB OECs	33616
endogenous Schwann cells	33649
the lesion site Interactions between OECs and glia other	33677
the lesion site Interactions	33677
OECs and glia other	33714
OECs	33714
glia other	33723
astrocytes	33739
regeneration outcomes	33782
Schwann cells -LRB- SCs -RRB-	33805
Schwann cells	33805
SCs	33820
regeneration	33851
their ability to promote regeneration and remyelination after CNS lesions -LRB- Bunge , 2002 -RRB-	33894
regeneration and remyelination	33919
CNS lesions -LRB- Bunge , 2002 -RRB-	33956
CNS lesions	33956
Bunge	33969
2002	33976
We	33983
part of the mechanism whereby OECs may stimulate regeneration	34017
part	34017
the mechanism whereby OECs may stimulate regeneration	34025
the mechanism	34025
OECs	34047
regeneration	34066
their ability to promote the infiltration of endogenous SCs into the spinal cord -LRB- Ramer et al. , 2004b -RRB-	34086
the infiltration of endogenous SCs	34111
the infiltration	34111
endogenous SCs	34131
the spinal cord -LRB- Ramer et al. , 2004b -RRB-	34151
the spinal cord	34151
Ramer	34168
et al. , 2004b	34174
et al.	34174
2004b	34182
we	34199
OB OECs	34222
SC infiltration in this lesion paradigm	34243
SC infiltration	34243
this lesion paradigm	34262
Immunostaining of all groups for the rat-specific low-affinity nerve growth factor receptor mp75 compared with GFAP and GFP + OECs	34284
Immunostaining	34284
all groups for the rat-specific low-affinity nerve growth factor receptor mp75 compared with GFAP and GFP + OECs	34302
all groups	34302
the rat-specific low-affinity nerve growth factor receptor mp75 compared with GFAP and GFP + OECs	34317
the rat-specific low-affinity nerve growth factor receptor mp75	34317
GFAP and GFP + OECs	34395
GFAP	34395
GFP + OECs	34404
endogenous cells	34423
p75	34451
areas with OECs within the lesion site -LRB- Fig. 4B , D -RRB-	34458
areas	34458
OECs within the lesion site -LRB- Fig. 4B , D -RRB-	34469
OECs	34469
the lesion site -LRB- Fig. 4B , D -RRB-	34481
the lesion site	34481
Fig. 4B , D	34498
Fig. 4B	34498
D	34506
the injection points in LP - -LRB- Fig. 4A -RRB- and OBtreated rats -LRB- Fig. 4C -RRB-	34534
the injection points in LP - -LRB- Fig. 4A -RRB-	34534
the injection points	34534
LP	34558
Fig. 4A	34563
OBtreated rats -LRB- Fig. 4C -RRB-	34576
OBtreated rats	34576
Fig. 4C	34592
We	34602
previously these rat p75 + cells as SCs using other markers for rat SCs -LRB- Chernousov et al. , 1999 ; Ramer et al. , 2004b -RRB-	34621
these rat p75	34632
cells as SCs using other markers for rat SCs -LRB- Chernousov et al. , 1999 ; Ramer et al. , 2004b -RRB-	34647
cells	34647
SCs using other markers for rat SCs -LRB- Chernousov et al. , 1999 ; Ramer et al. , 2004b -RRB-	34656
SCs	34656
other markers for rat SCs -LRB- Chernousov et al. , 1999 ; Ramer et al. , 2004b -RRB-	34666
other markers	34666
rat SCs -LRB- Chernousov et al. , 1999 ; Ramer et al. , 2004b -RRB-	34684
rat SCs	34684
Chernousov	34693
et al. , 1999 ; Ramer et al. , 2004b	34704
et al.	34704
1999 ; Ramer et al.	34712
1999	34712
Ramer et al.	34718
Ramer	34718
et al.	34724
2004b	34732
Ingression of Schwann cells into the spinal cord parenchyma -LRB- measured from the GFAP lesion boundary -RRB-	34740
Ingression of Schwann cells into the spinal cord parenchyma	34740
Ingression	34740
Schwann cells into the spinal cord parenchyma	34754
Schwann cells	34754
the spinal cord parenchyma	34773
the GFAP lesion boundary	34815
OEC-treated groups , in which Schwann cells were found maximally at 350 µm	34868
OEC-treated groups	34868
Schwann cells	34897
350 µm	34935
the lesion site	34947
Schwann cell infiltration	34964
control animals -LRB- Fig. 4E -RRB-	35009
control animals	35009
Fig. 4E	35026
80 µm of the lesion boundary	35064
80 µm	35064
the lesion boundary	35073
SCs that infiltrated after OEC transplantation	35094
SCs	35094
OEC transplantation	35121
LP -LRB- Fig. 4B -RRB- and OB -LRB- Fig. 4C -RRB- OECs ,	35167
LP	35167
Fig. 4B	35171
OB -LRB- Fig. 4C -RRB- OECs	35184
OB	35184
Fig. 4C	35188
OECs	35197
CNS astrocytes -LRB- Fig. 4B , D -RRB-	35219
CNS astrocytes	35219
Fig. 4B , D	35235
Fig. 4B	35235
D	35243
This	35247
some of the proregenerative effects of LP and OB OEC transplantation	35266
some	35266
the proregenerative effects of LP and OB OEC transplantation	35274
the proregenerative effects	35274
LP and OB OEC transplantation	35305
part , to their ability to recruit , activate , or cooperate with endogenous Schwann cells	35359
part	35359
their ability to recruit , activate , or cooperate with endogenous Schwann cells	35368
endogenous Schwann cells	35422
Axonal sprouting into the lesion site	35448
Axonal	35448
the lesion site	35470
rats transplanted rostrocaudally with LP OEC animals The results so far suggest distinct biological differences in the ability of OB and LP OECs to promote repair	35502
rats	35502
LP OEC animals	35540
The results	35555
distinct biological differences in the ability of OB and LP OECs	35582
distinct biological differences	35582
the ability of OB and LP OECs	35617
the ability	35617
OB and LP OECs	35632
repair	35658
We	35666
these findings	35683
-LRB- 1 -RRB- differences in axonal outgrowth , -LRB- 2 -RRB- differences in angiogenesis , and -LRB- 3 -RRB- differences in the directionality of these parameters in relation to transplanted cells	35719
-LRB- 1 -RRB- differences in axonal outgrowth	35719
differences	35723
axonal outgrowth	35738
-LRB- 2 -RRB- differences in angiogenesis	35756
differences	35760
angiogenesis	35775
-LRB- 3 -RRB- differences in the directionality of these parameters in relation to transplanted cells	35793
differences	35797
the directionality of these parameters in relation to transplanted cells	35812
the directionality	35812
these parameters in relation to transplanted cells	35834
these parameters	35834
relation to transplanted cells	35854
relation	35854
transplanted cells	35866
This	35886
us	35903
factors	35936
an SCI lesion area	35958
repair	35999
the lesion site	36017
the location of the OECs	36044
the location	36044
the OECs	36060
repair and regeneration parameters	36091
Large-caliber axons expressing NF	36127
Large-caliber axons	36127
NF	36158
differences	36174
degree of sprouting depending on both whether LP -LRB- Fig. 5A , B -RRB- or OB -LRB- Fig. 5C , D -RRB- OECs were transplanted and whether introduction was direct or rostrocaudal	36189
degree	36189
both whether LP -LRB- Fig. 5A , B -RRB- or OB -LRB- Fig. 5C , D -RRB- OECs were transplanted and whether introduction was direct or rostrocaudal	36222
both	36222
LP -LRB- Fig. 5A , B -RRB- or OB -LRB- Fig. 5C , D -RRB- OECs	36235
LP -LRB- Fig. 5A , B -RRB-	36235
LP	36235
Fig. 5A , B	36239
Fig. 5A	36239
B	36247
OB -LRB- Fig. 5C , D -RRB- OECs	36253
OB	36253
Fig. 5C , D	36257
Fig. 5C	36257
D	36265
OECs	36268
introduction	36303
all animals	36347
some axons	36360
cavity-free areas of the lesion site	36385
cavity-free areas	36385
the lesion site	36406
cell delivery approach	36437
the distribution of axon growth	36465
the distribution	36465
axon growth	36485
treatment groups	36524
the lesion site	36564
rats that received direct transplants of LP and OB OECs	36584
rats	36584
direct transplants of LP and OB OECs	36603
direct transplants	36603
LP and OB OECs	36625
axonal growth	36641
the caudal lesion boundary -LRB- four of four for each group -RRB- -LRB- Fig. 5B , D -RRB-	36682
the caudal lesion boundary -LRB- four of four for each group -RRB-	36682
the caudal lesion boundary	36682
four of four for each group	36710
four	36710
four	36718
each group	36727
Fig. 5B , D	36740
Fig. 5B	36740
D	36748
addition	36755
some NF + axons	36774
some NF	36774
axons	36783
the lesion site	36809
direct transplant groups	36833
zones devoid of NF + axons	36859
zones	36859
NF + axons	36875
NF	36875
axons	36879
the GFAP-immunoreactive border -LRB- LP direct , n = 3 of 4 ; OB direct , n = 4 of 4 -RRB-	36912
the GFAP-immunoreactive border	36912
LP direct , n = 3 of 4 ; OB direct , n = 4 of 4	36944
LP direct	36944
LP	36944
direct	36947
n = 3 of 4 ; OB direct	36955
n = 3 of 4	36955
n = 3	36955
n	36955
3	36959
4	36964
OB direct	36967
OB	36967
direct	36970
n = 4 of 4	36978
n = 4	36978
n	36978
4	36982
4	36987
Rats that received rostrocaudal LPOEC transplants -LRB- Fig. 5A -RRB-	36991
Rats that received rostrocaudal LPOEC transplants	36991
Rats	36991
rostrocaudal LPOEC transplants	37010
Fig. 5A	37042
a higher incidence of NF + axons within the lesion site	37064
a higher incidence	37064
NF + axons within the lesion site	37086
NF + axons	37086
the lesion site	37103
all other groups	37133
NF + reactivity	37164
NF	37164
reactivity	37168
the lesion site	37207
the astrocytic border	37237
rats that received LP or OB OECs transplanted directly into the lesion	37274
rats	37274
LP or OB OECs transplanted directly into the lesion	37293
LP or OB OECs	37293
the lesion	37334
Rats that received rostrocaudal OB OEC transplants	37346
Rats	37346
rostrocaudal OB OEC transplants	37365
the lowest incidence of NF + reactivity within the lesion site -LRB- n = 4 of 4 -RRB- -LRB- Fig. 5C -RRB-	37410
the lowest incidence of NF	37410
the lowest incidence	37410
NF	37434
reactivity within the lesion site -LRB- n = 4 of 4 -RRB- -LRB- Fig. 5C -RRB-	37438
reactivity	37438
the lesion site -LRB- n = 4 of 4 -RRB- -LRB- Fig. 5C -RRB-	37456
the lesion site -LRB- n = 4 of 4 -RRB-	37456
the lesion site	37456
n = 4 of 4	37473
n = 4	37473
n	37473
4	37477
4	37482
Fig. 5C	37486
the differences in axon growth	37521
the differences	37521
axon growth	37540
the lesion site	37559
all treatment groups	37578
densitometry of NF + pixels	37600
densitometry	37600
NF + pixels	37616
NF	37616
pixels	37620
the GFAP-reactive border	37654
NF + pixels within this area -LRB- Fig. 5E -RRB-	37692
NF + pixels	37692
this area -LRB- Fig. 5E -RRB-	37710
this area	37710
Fig. 5E	37721
A significant increase in growth within the lesion	37731
A significant increase	37731
growth within the lesion	37757
growth	37757
the lesion	37771
rostrocaudal transplantation of LP OECs	37798
rostrocaudal transplantation	37798
LP OECs	37830
all other groups -LRB- n = 4 ; p ≤ 0.001 , all groups -RRB- -LRB- Fig. 5E -RRB-	37852
all other groups -LRB- n = 4 ; p ≤ 0.001 , all groups -RRB-	37852
all other groups	37852
n = 4 ; p ≤ 0.001 , all groups	37870
n = 4 ; p ≤ 0.001 , all	37870
n = 4	37870
n	37870
4	37872
p ≤ 0.001 , all	37875
p	37875
≤ 0.001	37876
groups	37888
Fig. 5E	37897
rats that received OB OECs directly at the lesion site	37916
rats	37916
OB OECs	37935
the lesion site	37955
significantly more NF + axons	37984
significantly more NF	37984
axons	38007
the lesion compared with rostrocaudal OB OEC transplants -LRB- n = 4 , all groups ; p ≤ 0.05 -RRB-	38020
the lesion	38020
rostrocaudal OB OEC transplants -LRB- n = 4 , all groups ; p ≤ 0.05 -RRB-	38045
rostrocaudal OB OEC transplants	38045
n = 4 , all groups ; p ≤ 0.05	38078
n = 4	38078
n	38078
4	38082
groups ; p ≤ 0.05	38089
groups	38089
p ≤ 0.05	38097
p	38097
≤ 0.05	38099
These results	38108
cell type and delivery method	38135
cell type	38135
delivery method	38149
the pattern of growth of sprouting axons	38191
the pattern	38191
growth of sprouting axons	38206
growth	38206
axons	38226
their ability	38250
the lesion site	38277
Directional angiogenesis	38294
OEC treatment Much of the axonal outgrowth reported above , particularly in rats treated by rostrocaudal LP OEC transplantation -LRB- Fig. 5A -RRB- , appeared directed toward the lesion site	38334
OEC treatment	38334
Much of the axonal outgrowth	38348
Much	38348
the axonal outgrowth	38356
rats treated by rostrocaudal LP OEC transplantation -LRB- Fig. 5A -RRB-	38409
rats	38409
rostrocaudal LP OEC transplantation -LRB- Fig. 5A -RRB-	38425
rostrocaudal LP OEC transplantation	38425
Fig. 5A	38462
the lesion site	38497
We	38514
angiogenesis in the lesion site	38544
angiogenesis	38544
the lesion site	38560
LP OEC transplantation	38589
many axons	38622
blood vessel laminas -LRB- Ramer et al. , 2004b -RRB-	38646
blood vessel laminas	38646
Ramer	38668
et al. , 2004b	38674
et al.	38674
2004b	38682
an angiogenic response	38703
axon growth	38742
contusive injury -LRB- Loy et al. , 2002 -RRB-	38787
contusive injury	38787
Loy	38805
et al. , 2002	38809
et al.	38809
2002	38817
it	38835
the direction of axon growth	38855
the direction	38855
axon growth	38872
the direction of blood vessel growth	38902
the direction	38902
blood vessel growth	38919
this	38944
different transplantation strategies	38973
ing axons	39045
the spinal cord instead of becoming entangled at the lesion site	39085
the spinal cord	39085
the lesion site	39134
the extent and directionality of blood vessel growth	39161
the extent and directionality	39161
blood vessel growth	39194
anti-RECA and GFAP detection	39215
anti-RECA	39215
GFAP detection	39229
blood vessels	39266
the lesion site -LRB- Fig. 6A -- E -RRB-	39298
the lesion site	39298
Fig. 6A -- E	39315
Fig. 6A	39315
E	39323
directionality	39338
montages of Z-stacked images of RECA-immunoreactive endothelia	39354
montages	39354
Z-stacked images of RECA-immunoreactive endothelia	39366
Z-stacked images	39366
RECA-immunoreactive endothelia	39386
a threshold intensity -LRB- applied within and across groups -RRB-	39431
a threshold intensity	39431
groups	39480
a best-fit line along their linear axis	39511
a best-fit line	39511
their linear axis	39533
an algorithm programmed in Matlab , to determine their direction of growth -LRB- Fig. 6F -RRB-	39558
an algorithm	39558
Matlab	39585
their direction of growth -LRB- Fig. 6F -RRB-	39606
their direction	39606
growth -LRB- Fig. 6F -RRB-	39625
growth	39625
Fig. 6F	39633
The predicted intersection points of lines	39643
The predicted intersection points	39643
lines	39680
contour maps of most likely endothelial convergence -LRB- Fig. 6G -- K -RRB-	39714
contour maps	39714
most likely endothelial convergence -LRB- Fig. 6G -- K -RRB-	39730
most likely endothelial convergence	39730
Fig. 6G -- K	39767
Fig. 6G	39767
K	39775
The density of intersections within the lesion site	39779
The density	39779
intersections within the lesion site	39794
intersections	39794
the lesion site	39815
a baseline of intersections	39849
a baseline	39849
intersections	39863
the same lesion area , randomly placed throughout the same spinal cord	39884
the same lesion area	39884
the same spinal cord	39933
This	39955
a measure of the extent of directionality of blood vessels toward the lesion site	39969
a measure	39969
the extent of directionality of blood vessels toward the lesion site	39982
the extent	39982
directionality of blood vessels toward the lesion site	39996
directionality	39996
blood vessels toward the lesion site	40014
blood vessels	40014
the lesion site	40035
lesion area	40067
number of blood vessels	40087
number	40087
blood vessels	40097
Scores greater than zero	40112
Scores	40112
zero	40132
directionality of blood vessels toward the lesion site	40156
directionality	40156
blood vessels toward the lesion site	40174
blood vessels	40174
the lesion site	40195
all OEC-treated rats	40215
there	40237
significantly greater numbers of blood vessels	40248
significantly greater numbers	40248
blood vessels	40281
control animals -LRB- Table 1 -RRB-	40303
control animals	40303
Table 1	40320
there	40339
a significant and 1.9-fold increase in directionality of blood vessel growth toward the lesion site in rats that received OEC transplants compared with the random endothelial growth in control animals -LRB- Table 1 -RRB-	40349
a significant and 1.9-fold increase	40349
directionality of blood vessel growth toward the lesion site in rats that received OEC transplants compared with the random endothelial growth in control animals -LRB- Table 1 -RRB-	40389
directionality	40389
blood vessel growth toward the lesion site in rats that received OEC transplants compared with the random endothelial growth in control animals -LRB- Table 1 -RRB-	40407
blood vessel growth	40407
the lesion site in rats that received OEC transplants compared with the random endothelial growth in control animals -LRB- Table 1 -RRB-	40434
the lesion site	40434
rats that received OEC transplants compared with the random endothelial growth in control animals -LRB- Table 1 -RRB-	40453
rats	40453
OEC transplants	40472
the random endothelial growth in control animals	40502
the random endothelial growth	40502
control animals	40535
Table 1	40552
Rats that were directly transplanted with OB OECs	40562
Rats	40562
OB OECs	40604
the most significant blood vessel growth	40625
the lesion site	40682
Vascularization and enhanced regeneration	40699
Vascularization	40699
enhanced regeneration	40719
the peripheral nervous system -LRB- Hobson et al. , 2000 -RRB-	40769
the peripheral nervous system	40769
Hobson	40800
et al. , 2000	40807
et al.	40807
2000	40815
the increase in blood vessels and their direction of growth in all OEC-treated rats	40826
the increase in blood vessels	40826
the increase	40826
blood vessels	40842
their direction of growth in all OEC-treated rats	40860
their direction	40860
growth in all OEC-treated rats	40879
growth	40879
all OEC-treated rats	40889
directed axon growth	40920
the CNS	40948
Autotomy	40957
OB OEC	40980
elevated by LP OEC transplantation Transplantation of either LP or OB OECs	40991
elevated	40991
LP OEC transplantation Transplantation of either LP or OB OECs	41003
LP OEC transplantation Transplantation	41003
either LP or OB OECs	41045
LP	41052
OB OECs	41058
the enhanced growth of NF axons within the lesion site	41078
the enhanced growth	41078
NF axons within the lesion site	41101
NF axons	41101
the lesion site	41118
it	41144
these axons	41166
functional connections , either appropriate or inappropriate , with target neurons	41183
functional connections	41183
target neurons	41249
27 d after lesion and transplantation	41268
27 d	41268
lesion and transplantation	41279
autotomy	41307
some rats	41332
we	41346
the degree of autotomy	41377
the degree	41377
autotomy	41391
groups	41415
this measure	41430
an admittedly negative behavioral readout for changes in functional connectivity	41458
an admittedly negative behavioral readout	41458
changes in functional connectivity	41504
changes	41504
functional connectivity	41515
Autotomy	41540
the self-attack of a -LRB- partially -RRB- denervated limb , characterized by excessive licking , grooming , and biting of the anesthetic limb , eventually resulting in digit amputation -LRB- Kauppila , 1998 ; Zimmermann , 2001 -RRB-	41552
the self-attack	41552
a -LRB- partially -RRB-	41571
limb , characterized by excessive licking , grooming , and biting of the anesthetic limb , eventually resulting in digit amputation -LRB- Kauppila , 1998 ; Zimmermann , 2001 -RRB-	41596
limb	41596
the anesthetic limb	41662
digit amputation -LRB- Kauppila , 1998 ; Zimmermann , 2001 -RRB-	41707
digit amputation	41707
Kauppila , 1998 ; Zimmermann , 2001	41725
Kauppila	41725
1998 ; Zimmermann	41735
1998	41735
Zimmermann	41741
2001	41753
Autotomy	41760
the methods described by Wall -LRB- 1979 -RRB- , in which a total of three points were awarded for the attack of each digit : 1 point for nail removal , 2 points for amputation up to the first knuckle , and 3 points for total digit removal	41786
the methods described by Wall -LRB- 1979 -RRB- , in which a total of three points were awarded for the attack of each digit	41786
the methods	41786
Wall -LRB- 1979 -RRB- , in which a total of three points were awarded for the attack of each digit	41811
Wall -LRB- 1979 -RRB-	41811
Wall	41811
1979	41817
a total of three points	41833
a total	41833
three points	41844
the attack of each digit	41874
the attack	41874
each digit	41888
1 point for nail removal	41900
1 point	41900
nail removal	41912
2 points for amputation up to the first knuckle	41926
2 points	41926
amputation up to the first knuckle	41939
amputation	41939
the first knuckle	41956
3 points for total digit removal	41979
3 points	41979
total digit removal	41992
a total of 15 possible points for each paw -LRB- Fig. 7A -RRB-	42017
a total	42017
15 possible points for each paw -LRB- Fig. 7A -RRB-	42028
15 possible points	42028
each paw -LRB- Fig. 7A -RRB-	42051
each paw	42051
Fig. 7A	42061
each rat	42075
the affected right hindpaw	42085
the left hindpaw , which served as an internal control	42134
the left hindpaw	42134
an internal control	42168
Rats that received direct transplants of LP OECs -LRB- n 4 -RRB-	42189
Rats that received direct transplants of LP OECs	42189
Rats	42189
direct transplants of LP OECs	42208
direct transplants	42208
LP OECs	42230
n 4	42239
the greatest autotomy scores , significantly greater than either control -LRB- n = 4 -RRB- or directly transplanted OB rats -LRB- n = 5 ; p ≤ 0.05 and p ≤ 0.01 -RRB- -LRB- Fig. 7B -RRB-	42248
the greatest autotomy scores	42248
either control -LRB- n = 4 -RRB-	42305
either control	42305
n	42321
4	42325
OB rats -LRB- n = 5 ; p ≤ 0.05 and p ≤ 0.01 -RRB- -LRB- Fig. 7B -RRB-	42353
OB rats -LRB- n = 5 ; p ≤ 0.05 and p ≤ 0.01 -RRB-	42353
OB rats	42353
n = 5 ; p ≤ 0.05 and p ≤ 0.01	42362
n = 5 ; p ≤ 0.05	42362
n = 5	42362
n	42362
5	42366
p ≤ 0.05	42369
p	42369
0.05	42373
p ≤ 0.01	42382
p	42382
≤ 0.01	42384
Fig. 7B	42393
Rostrocaudally transplanted OB OEC	42403
rats	42438
lower autotomy	42456
transplanted LP rats and control rats -LRB- n = 4 , 5 , 5 ; p ≤ 0.05 and p ≤ 0.05 , respectively -RRB- -LRB- Fig. 7B -RRB-	42491
transplanted LP rats	42491
control rats -LRB- n = 4 , 5 , 5 ; p ≤ 0.05 and p ≤ 0.05 , respectively -RRB- -LRB- Fig. 7B -RRB-	42516
control rats -LRB- n = 4 , 5 , 5 ; p ≤ 0.05 and p ≤ 0.05 , respectively -RRB-	42516
control rats	42516
n = 4 , 5 , 5 ; p ≤ 0.05 and p ≤ 0.05 , respectively	42530
n = 4	42530
n	42530
4	42534
5 , 5 ; p ≤ 0.05	42537
5 , 5	42537
5	42537
5	42540
p ≤ 0.05	42543
p	42543
0.05	42547
p ≤ 0.05 , respectively	42556
p	42556
≤ 0.05	42558
Fig. 7B	42581
LP OEC transplantation	42591
autotomy	42629
injection paradigm	42652
the incidence -LRB- OB , 2 of 8 rats ; LP , 6 of 10 rats -RRB- and extent of autotomy -LRB- 92 % less autotomy in OB rats -RRB-	42680
the incidence -LRB- OB , 2 of 8 rats ; LP , 6 of 10 rats -RRB- and extent of autotomy	42680
the incidence -LRB- OB , 2 of 8 rats ; LP , 6 of 10 rats -RRB-	42680
the incidence	42680
OB , 2 of 8 rats ; LP , 6 of 10 rats	42695
OB	42695
2 of 8 rats ; LP , 6 of 10 rats	42699
2 of 8 rats	42699
2	42699
8 rats	42704
LP , 6 of 10 rats	42712
LP	42712
6 of 10 rats	42716
6	42716
10 rats	42721
extent of autotomy	42734
extent	42734
autotomy	42744
92 % less autotomy in OB rats	42754
92 % less autotomy	42754
92 %	42754
OB rats	42775
OB-treated rats	42796
TH	42826
subP	42831
CGRPpositive axons	42842
LP or OB OEC transplantation	42893
LP and OB OECs	42938
that	42999
we	43034
the pattern of axon outgrowth from dorsal root afferents as well as different descending tracts	43045
the pattern	43045
axon outgrowth from dorsal root afferents as well as different descending tracts	43060
axon outgrowth from dorsal root afferents	43060
axon outgrowth	43060
dorsal root afferents	43080
different descending tracts	43113
We	43142
LP OEC transplantation	43172
the growth of 5-HT + and TH + axons , as well as some growth of dorsal root afferents	43206
the growth of 5-HT	43206
the growth	43206
5-HT	43220
TH + axons	43230
TH	43230
axons	43234
some growth of dorsal root afferents	43252
some growth	43252
dorsal root afferents	43267
CGRP	43300
+	43304
subP	43309
+	43313
Ramer et al. , 2004b	43316
Ramer	43316
et al.	43322
2004b	43330
We	43338
horizontal sections	43349
the lesion site	43377
the presence of these axonal subpopulations using the GFAP + border to identify the boundaries of the lesion site	43397
the presence	43397
these axonal subpopulations using the GFAP + border to identify the boundaries of the lesion site	43413
these axonal subpopulations	43413
the GFAP + border	43447
the boundaries of the lesion site	43476
the boundaries	43476
the lesion site	43494
Montaged , Z-stacked sections	43511
Montaged	43511
Z-stacked sections	43521
the total number of positive pixels	43558
the total number	43558
positive pixels	43578
the lesion site	43601
areas 0.5 and 1 mm rostral and caudal	43636
areas 0.5 and 1	43636
mm rostral and caudal	43652
the lesion	43677
We	43689
the presence of different axonal subtypes	43709
the presence	43709
different axonal subtypes	43725
24 h	43754
lesion and transplantation	43765
all axons tested	43807
all axons	43807
the lesion site	43841
the rostral and caudal lesion boundaries -LRB- supplemental Fig. 2 , available at www.jneurosci.org as supplemental material -RRB-	43890
the rostral	43890
caudal lesion boundaries -LRB- supplemental Fig. 2 , available at www.jneurosci.org as supplemental material -RRB-	43906
caudal lesion boundaries	43906
supplemental Fig. 2 , available at www.jneurosci.org as supplemental material	43932
supplemental Fig. 2 , available at www.jneurosci.org	43932
supplemental Fig.	43932
2	43950
www.jneurosci.org	43966
supplemental material	43987
28 d	44014
rats that received LP OECs -LRB- Fig. 8A -RRB- and OB OECs -LRB- Fig. 8B -RRB-	44023
rats	44023
LP OECs -LRB- Fig. 8A -RRB- and OB OECs -LRB- Fig. 8B -RRB-	44042
LP OECs -LRB- Fig. 8A -RRB-	44042
LP OECs	44042
Fig. 8A	44051
OB OECs -LRB- Fig. 8B -RRB-	44064
OB OECs	44064
Fig. 8B	44073
subP-positive axons	44083
the lesion site	44121
caudal	44156
the lesion site	44166
No significant differences in axonal outgrowth of subtypes	44183
No significant differences	44183
axonal outgrowth of subtypes	44213
axonal outgrowth	44213
subtypes	44233
direct and rostrocaudally transplanted rats within LP or OB OEC treatment groups	44264
direct and rostrocaudally transplanted rats	44264
LP or OB OEC treatment groups	44315
both sets of data for each OEC subtype	44350
both sets	44350
data for each OEC subtype	44363
data	44363
each OEC subtype	44372
OB-transplanted rats	44420
subP reactivity	44442
rostral	44468
the lesion site -LRB- Fig. 8B , inset -RRB- , whereas less reactivity was observed at this location in LP OEC -LRB- Fig. 8A , inset -RRB- transplanted rats	44479
the lesion site -LRB- Fig. 8B , inset -RRB-	44479
the lesion site	44479
Fig. 8B , inset	44496
Fig. 8B	44496
less reactivity	44521
this location in LP OEC -LRB- Fig. 8A , inset -RRB- transplanted rats	44553
this location	44553
LP OEC -LRB- Fig. 8A , inset -RRB- transplanted rats	44570
LP OEC -LRB- Fig. 8A , inset -RRB-	44570
LP OEC	44570
Fig. 8A , inset	44578
Fig. 8A	44578
rats	44607
subP-positive axons	44613
all points in rats that received OB OECs compared with LP OECs -LRB- n = 4 each group ; p ≤ 0.05 all levels -RRB- -LRB- Fig. 8C -RRB-	44665
all points	44665
rats that received OB OECs compared with LP OECs -LRB- n = 4 each group ; p ≤ 0.05 all levels -RRB- -LRB- Fig. 8C -RRB-	44679
rats	44679
OB OECs compared with LP OECs -LRB- n = 4 each group ; p ≤ 0.05 all levels -RRB- -LRB- Fig. 8C -RRB-	44698
OB OECs	44698
LP OECs -LRB- n = 4 each group ; p ≤ 0.05 all levels -RRB- -LRB- Fig. 8C -RRB-	44720
LP OECs -LRB- n = 4 each group ; p ≤ 0.05 all levels -RRB-	44720
LP OECs	44720
n = 4 each group ; p ≤ 0.05 all levels	44729
n = 4 each group ; p ≤ 0.05	44729
n = 4 each group	44729
n	44729
= 4 each group	44731
4	44733
p ≤ 0.05	44747
p	44747
≤ 0.05	44750
all levels	44756
Fig. 8C	44769
This	44779
OB OECs	44798
LP OECs	44830
the sprouting of subP-positive axons after injury	44851
the sprouting	44851
subP-positive axons after injury	44868
subP-positive axons	44868
injury	44894
CGRP-positive nociceptive/temperature responsive afferents	44902
nociceptive/temperature	44916
LP OEC transplantation -LRB- Ramer et al. , 2004b -RRB-	44984
LP OEC transplantation	44984
Ramer	45008
et al. , 2004b	45014
et al.	45014
2004b	45022
their sprouting	45034
their	45034
pain sensation	45063
SCI -LRB- Jang et al. , 2004 -RRB-	45084
SCI	45084
Jang	45089
et al. , 2004	45094
et al.	45094
2004	45102
Detection of CGRP-positive axons in rats that received LP OECs -LRB- Fig. 8D -RRB- and OB OECs -LRB- Fig. 8E -RRB-	45109
Detection	45109
CGRP-positive axons in rats	45122
CGRP-positive axons	45122
rats	45145
LP OECs -LRB- Fig. 8D -RRB- and OB OECs -LRB- Fig. 8E -RRB-	45164
LP OECs -LRB- Fig. 8D -RRB-	45164
LP OECs	45164
Fig. 8D	45173
OB OECs -LRB- Fig. 8E -RRB-	45186
OB OECs	45186
Fig. 8E	45195
similar sprouting patterns between groups , although LP OECs slightly increased sprouting 0.5 mmrostral to the lesion site -LRB- n 4 each group -RRB- -LRB- Fig. 8F -RRB- and demonstrated increased sprouting at the rostral lesion border -LRB- Fig. 8D , inset , F	45213
patterns between groups , although LP OECs slightly increased sprouting 0.5 mmrostral to the lesion site -LRB- n 4 each group -RRB- -LRB- Fig. 8F -RRB- and demonstrated increased sprouting at the rostral lesion border -LRB- Fig. 8D , inset ,	45231
patterns	45231
groups , although LP OECs slightly increased sprouting 0.5 mmrostral to the lesion site -LRB- n 4 each group -RRB- -LRB- Fig. 8F -RRB- and demonstrated increased sprouting at the rostral lesion border -LRB- Fig. 8D , inset ,	45248
groups	45248
LP OECs	45265
0.5 mmrostral	45302
the lesion site -LRB- n 4 each group -RRB- -LRB- Fig. 8F -RRB-	45318
the lesion site -LRB- n 4 each group -RRB-	45318
the lesion site	45318
n 4 each group	45335
n 4	45335
each group	45340
Fig. 8F	45353
the rostral lesion border -LRB- Fig. 8D , inset	45402
the rostral lesion border -LRB- Fig. 8D ,	45402
Both types of OEC did	45449
Both types	45449
OEC did	45463
OEC	45463
the growth of CGRP-positive axons over control animals	45489
the growth	45489
CGRP-positive axons over control animals	45503
CGRP-positive axons	45503
control animals	45528
the lesion site , in which no sparing of CGRPpositive axons was visible at 24 h after lesion	45565
the lesion site	45565
no sparing of CGRPpositive axons	45591
no sparing	45591
CGRPpositive axons	45605
24 h	45639
lesion	45650
No significant differences in CGRPpositive sprouting	45658
No significant differences	45658
CGRPpositive sprouting	45688
CGRPpositive	45688
direct and rostrocaudally transplanted rats	45733
raphespinal 5-HTpositive axons appeared similar in both LP - and OB-treated rats -LRB- Fig. 8G , H -RRB- and was extensive compared with CGRP + and subP	45791
raphespinal 5-HTpositive axons	45791
both LP - and OB-treated rats -LRB- Fig. 8G , H -RRB-	45842
both LP	45842
OB-treated rats	45855
Fig. 8G , H	45872
Fig. 8G	45872
H	45880
CGRP + and subP	45915
CGRP	45915
and subP	45921
no significant differences	45942
transplant groups -LRB- n = 4 for all groups -RRB- -LRB- Fig. 8I -RRB-	45991
transplant groups -LRB- n = 4 for all groups -RRB-	45991
transplant groups	45991
n = 4 for all groups	46010
n = 4	46010
n	46010
4	46014
all groups	46020
Fig. 8I	46033
5-HT-positive axons	46043
the lesion site -LRB- Fig. 8G , H , insets -RRB-	46122
the lesion site	46122
Fig. 8G , H , insets	46139
Fig. 8G	46139
H	46147
insets	46150
contrast	46162
detection of TH	46172
detection	46172
TH	46185
significantly more TH-positive axons rostral	46197
the lesion site	46256
rats that received LP OECs compared with OB OECs -LRB- Fig. 8J -- L -RRB-	46275
rats	46275
LP OECs	46294
OB OECs -LRB- Fig. 8J -- L -RRB-	46316
OB OECs	46316
Fig. 8J -- L	46325
Fig. 8J	46325
L	46333
This	46337
the rostral lesion boundary , in which THpositive axons were increased in LPtransplanted -LRB- Fig. 8J , inset -RRB- compared with OB-transplanted -LRB- Fig. 8I , inset -RRB- rats	46370
the rostral lesion boundary	46370
THpositive axons	46408
LPtransplanted -LRB- Fig. 8J , inset -RRB- compared with OB-transplanted -LRB- Fig. 8I , inset -RRB- rats	46443
LPtransplanted -LRB- Fig. 8J , inset -RRB-	46443
LPtransplanted	46443
Fig. 8J , inset	46459
Fig. 8J	46459
OB-transplanted -LRB- Fig. 8I , inset -RRB- rats	46489
OB-transplanted -LRB- Fig. 8I , inset -RRB-	46489
OB-transplanted	46489
Fig. 8I , inset	46506
Fig. 8I	46506
rats	46522
neither 5-HT	46536
TH-positive axons	46554
the lesion site 24 h	46592
lesion , the transplanted LP and OB OECs	46619
lesion	46619
the transplanted LP	46627
OB OECs	46651
growth of these axon subtypes	46674
growth	46674
these axon subtypes	46684
Discussion OECs	46705
prime candidates	46746
cell-based therapies	46767
the injured CNS -LRB- Lakatos and Franklin , 2002 -RRB-	46798
the injured CNS	46798
Lakatos and Franklin , 2002	46815
Lakatos	46815
Franklin , 2002	46827
Franklin	46827
2002	46837
some OB OEC transplantation experiments	46852
different degrees of functional recovery	46907
different degrees	46907
functional recovery	46928
SCI -LRB- Ramon-Cueto et al. , 2000 ; Keyvan - Fouladi et al. , 2003 ; Garcia-Alias et al. , 2004 -RRB-	46953
SCI	46953
Ramon-Cueto	46958
et al. , 2000 ; Keyvan - Fouladi et al. , 2003 ; Garcia-Alias et al. , 2004	46970
et al.	46970
2000 ; Keyvan - Fouladi et al. , 2003 ; Garcia-Alias et al.	46978
2000 ; Keyvan	46978
2000	46978
Keyvan	46984
Fouladi et al. , 2003	46992
Fouladi	46992
et al. , 2003	47000
et al.	47000
2003	47008
Garcia-Alias et al.	47014
Garcia-Alias	47014
et al.	47027
2004	47035
cell preparations containing LP OECs	47042
cell preparations	47042
LP OECs	47071
human SCI	47119
the assumption that LP and OB OECs are functionally equivalent -LRB- Senior , 2002 ; Huang et al. , 2003 ; Rabinovich et al. , 2003 -RRB-	47138
the assumption	47138
LP and OB OECs	47158
Senior , 2002 ; Huang et al. , 2003 ; Rabinovich et al. , 2003	47202
Senior	47202
2002 ; Huang et al. , 2003 ; Rabinovich et al.	47210
2002	47210
Huang et al. , 2003 ; Rabinovich et al.	47216
Huang	47216
et al. , 2003 ; Rabinovich et al.	47222
et al. , 2003	47222
et al.	47222
2003	47230
Rabinovich et al.	47236
Rabinovich	47236
et al.	47247
2003	47255
both mechanistic and clinical reasons	47266
we	47305
the effect of transplanting OB and LP OECs into lesioned spinal cord	47322
the effect	47322
OB and LP OECs	47350
lesioned spinal cord	47370
they	47411
significantly different regeneration outcomes	47424
OB OECs	47485
LP OECs	47494
lesion site and cavity area and increase sprouting of NF	47511
lesion site and cavity area and increase	47511
NF	47565
+ and TH + axons	47567
and TH	47568
axons	47576
autotomy	47601
contrast	47614
OB OEC transplantation	47624
lesion site area and cavity formation	47657
lesion site area	47657
cavity formation	47678
subP + axons	47718
subP	47718
axons	47724
the greatest directional angiogenesis	47744
addition	47786
rostrocaudal compared with direct transplantation	47796
rostrocaudal	47796
direct transplantation	47823
LP and OB OECs	47860
different abilities to migrate	47880
cell delivery method	47920
astrogliosis , NF + sprouting , and cavity formation	47963
astrogliosis , NF + sprouting	47963
astrogliosis , NF	47963
astrogliosis	47963
NF	47977
sprouting	47981
cavity formation	47996
The morphological and antigenic profiles of LP and OB OECs in culture -LRB- Fig. 1 -RRB-	48014
The morphological and antigenic profiles of LP and OB OECs in culture	48014
The morphological and antigenic profiles	48014
LP and OB OECs in culture	48058
LP and OB OECs	48058
culture	48076
Fig. 1	48085
OEC types	48111
their differing roles in PNS and CNS environments in the olfactory system , and expansion capacities in vitro ,	48148
their differing roles in PNS and CNS environments in the olfactory system	48148
their differing roles	48148
PNS and CNS environments	48173
the olfactory system	48201
expansion capacities in vitro	48227
expansion capacities	48227
vitro	48251
LP and OB OECs	48269
a priori	48327
transplantation	48371
LP andOBOECs	48430
28 d	48472
lesion	48483
more GFP LP OECs	48505
the lesion site	48541
GFP OB OECs	48566
the caudal injection point and lesion site -LRB- Fig. 2 -RRB-	48600
the caudal injection point and lesion site	48600
Fig. 2	48644
This distribution	48653
increased death of OB OECs at the lesion site or a greater loss of LP OECs at injection sites	48693
increased death	48693
OB OECs at the lesion site or a greater loss of LP OECs at injection sites	48712
OB OECs at the lesion site	48712
OB OECs	48712
the lesion site	48723
a greater loss of LP OECs at injection sites	48742
a greater loss	48742
LP OECs at injection sites	48760
LP OECs	48760
injection sites	48771
The resemblance in cell distribution of 28 d R/C OBand 7 d R/C LP rats , coupled with the increased survival ofOB OECs at 28 d ,	48788
The resemblance	48788
cell distribution of 28 d R/C OBand 7 d R/C LP rats	48807
cell distribution	48807
28 d R/C OBand 7 d R/C LP rats	48828
28 d R/C OBand	48828
7 d R/C LP rats	48843
the increased survival ofOB OECs at 28 d	48873
the increased survival ofOB OECs	48873
28 d	48909
the difference in cell distribution	48929
the difference	48929
cell distribution	48947
a result of intrinsic LP/OB OEC migration differences that resemble those we assayed in vitro -LRB- Fig. 2 -RRB-	48978
a result	48978
intrinsic LP/OB OEC migration differences that resemble those we assayed in vitro -LRB- Fig. 2 -RRB-	48990
intrinsic LP/OB OEC migration differences	48990
those we assayed in vitro	49046
those	49046
we	49052
Fig. 2	49073
The ability of OECs to differentially migrate into a lesion site	49082
The ability	49082
OECs to differentially migrate into a lesion site	49097
a lesion site	49133
important consequences in SCI , because ,	49158
important consequences	49158
SCI , because ,	49184
SCI	49184
because	49189
a dorsolateral funiculus lesion	49201
a cavity	49234
24 h	49252
injury when untreated -LRB- Ramer et al. , 2004b -RRB-	49263
injury when untreated	49263
injury	49263
Ramer	49286
et al. , 2004b	49292
et al.	49292
2004b	49300
The greater percentage of cavity in rats that received rostrocaudal OB OEC transplants	49308
The greater percentage	49308
cavity in rats that received rostrocaudal OB OEC transplants	49334
cavity	49334
rats that received rostrocaudal OB OEC transplants	49344
rats	49344
rostrocaudal OB OEC transplants	49363
the result of a retarded migration of OB OECs -LRB- Fig. 3 -RRB-	49416
the result	49416
a retarded migration of OB OECs -LRB- Fig. 3 -RRB-	49430
a retarded migration	49430
OB OECs -LRB- Fig. 3 -RRB-	49454
OB OECs	49454
Fig. 3	49463
The long-term presence of OECs at the lesion site	49472
The long-term presence	49472
OECs at the lesion site	49498
OECs	49498
the lesion site	49506
a major determinant of reduced cavity size	49536
a major determinant	49536
reduced cavity size	49559
rostrocaudal LP OEC transplantation	49588
cavity formation	49646
direct transplantation -LRB- in which fewer LP OECs survive -RRB- -LRB- Fig. 3 -RRB-	49677
direct transplantation -LRB- in which fewer LP OECs survive -RRB-	49677
direct transplantation	49677
fewer LP OECs	49710
Fig. 3	49734
The decreased lesion site area in rostrocaudally transplanted rats	49743
The decreased lesion site area	49743
rostrocaudally transplanted rats	49777
differences in astrocytic reactions	49835
differences	49835
astrocytic reactions	49850
rostrocaudal versus direct transplantation	49877
rostrocaudal	49877
direct transplantation	49897
Increased GFAP reactivity around the lesion site of rats with direct versus rostrocaudal transplants of both OEC types	49921
Increased GFAP reactivity	49921
the lesion site of rats with direct versus rostrocaudal transplants of both OEC types	49954
the lesion site	49954
rats with direct versus rostrocaudal transplants of both OEC types	49973
rats	49973
direct versus rostrocaudal transplants of both OEC types	49983
direct	49983
rostrocaudal transplants of both OEC types	49997
rostrocaudal transplants	49997
both OEC types	50025
LP and OB OECs	50054
similar interactions with astrocytes -LRB- Fig. 3 -RRB-	50078
similar interactions	50078
astrocytes -LRB- Fig. 3 -RRB-	50104
astrocytes	50104
Fig. 3	50116
the increased GFAP immunoreactivity in rats that received transplants directly into the lesion site	50134
the increased GFAP immunoreactivity	50134
rats that received transplants directly into the lesion site	50173
rats	50173
transplants	50192
the lesion site	50218
the acute presence of OECs within the lesion	50248
the acute presence	50248
OECs within the lesion	50270
OECs	50270
the lesion	50282
astrocyte division	50309
astrocytic hypertrophy -LRB- Fig. 3 -RRB-	50347
astrocytic hypertrophy	50347
Fig. 3	50371
Differences in astrogliosis	50380
Differences	50380
astrogliosis	50395
-LRB- 1 -RRB- unfavorable interactions between OECs and astrocytes , -LRB- 2 -RRB- an increased local immune response after direct transplantation , or -LRB- 3 -RRB- a favorable interaction between OECs and astrocytes that requires long-term survival of OECs	50425
-LRB- 1 -RRB- unfavorable interactions between OECs and astrocytes , -LRB- 2 -RRB- an increased local immune response after direct transplantation	50425
unfavorable interactions	50429
OECs and astrocytes , -LRB- 2 -RRB- an increased local immune response after direct transplantation	50462
OECs and astrocytes	50462
-LRB- 2 -RRB- an increased local immune response after direct transplantation	50483
an	50487
increased local immune response	50490
direct transplantation	50528
-LRB- 3 -RRB- a favorable interaction between OECs and astrocytes that requires long-term survival of OECs	50555
a favorable interaction	50559
OECs and astrocytes that requires long-term survival of OECs	50591
OECs and astrocytes	50591
long-term survival of OECs	50625
long-term survival	50625
OECs	50647
Increased astrogliosis	50653
unfavorable OEC -- astrocyte interactions	50698
unfavorable OEC	50698
astrocyte interactions	50714
astrocyte size , shape , and reactivity	50746
astrocyte size	50746
shape	50762
reactivity	50773
contact	50812
OB OECs -LRB- Lakatos et al. , 2000 , 2003 -RRB-	50825
OB OECs	50825
Lakatos	50834
et al. , 2000 , 2003	50842
et al.	50842
2000	50850
2003	50856
addition	50866
similar numbers of autofluorescent immune infiltrates	50876
similar numbers	50876
autofluorescent immune infiltrates	50895
the lesion site of rostrocaudally	50951
the lesion site	50951
transplanted animals -LRB- of the same cell type -RRB- , arguing that the immune response may contribute to , but is not responsible for ,	50998
transplanted animals -LRB- of the same cell type -RRB-	50998
transplanted animals	50998
the same cell type	51023
the immune response	51057
astrogliosis in directly transplanted animals	51134
astrogliosis	51134
directly transplanted animals	51150
the decrease in GFAP intensity in rostrocaudally transplanted rats	51192
the decrease	51192
GFAP intensity in rostrocaudally transplanted rats	51208
GFAP intensity	51208
rostrocaudally transplanted rats	51226
a favorable but necessarily prolonged interaction between OECs and astrocytes	51282
a favorable but necessarily prolonged interaction	51282
OECs and astrocytes	51340
this delivery approach	51369
OEC survival	51406
The association of OECs and astrocytes	51420
The association	51420
OECs and astrocytes	51439
astrogliosis	51483
a more permissive environment , allowing SC infiltration and axonal extension	51507
a more permissive environment	51507
SC infiltration and axonal extension	51547
SC infiltration	51547
axonal extension	51567
SC transplantation	51585
behavioral recovery	51617
SCI -LRB- Pearse et al. , 2004 ; Fouad et al. , 2005 -RRB-	51642
SCI	51642
Pearse	51647
et al. , 2004 ; Fouad et al. , 2005	51654
et al.	51654
2004 ; Fouad et al.	51662
2004	51662
Fouad et al.	51668
Fouad	51668
et al.	51674
2005	51682
their infiltration after OEC transplantation	51700
their infiltration	51700
OEC transplantation	51725
regeneration	51779
OEC type	51806
functional assessments performed after OB OEC transplantation	51825
functional assessments	51825
OB OEC transplantation	51864
positive outcome measures -LRB- Ramon-Cueto et al. , 2000 ; Keyvan-Fouladi et al. , 2003 ; Garcia-Alias et al. , 2004 -RRB-	51913
positive outcome measures	51913
Ramon-Cueto et al. , 2000 ; Keyvan-Fouladi et al. , 2003 ; Garcia-Alias et al. , 2004	51940
Ramon-Cueto	51940
et al. , 2000 ; Keyvan-Fouladi et al. , 2003 ; Garcia-Alias et al. , 2004	51952
et al. , 2000	51952
et al.	51952
2000	51960
Keyvan-Fouladi et al. , 2003	51966
Keyvan-Fouladi	51966
et al. , 2003	51981
et al.	51981
2003	51989
Garcia-Alias et al. , 2004	51995
Garcia-Alias	51995
et al. , 2004	52008
et al.	52008
2004	52016
the assumption that LP OECs would be similarly beneficial	52028
the assumption	52028
LP OECs	52048
The biological differences observed between LP and OB OECs in vitro -LRB- Fig. 2 -RRB- and after direct and rostrocaudal transplantation -LRB- Figs. 2 -- 4 -RRB-	52087
The biological differences	52087
LP and OB OECs in vitro -LRB- Fig. 2 -RRB-	52131
LP and OB OECs	52131
vitro	52149
Fig. 2	52156
direct and rostrocaudal transplantation -LRB- Figs. 2 -- 4 -RRB-	52174
direct and rostrocaudal transplantation	52174
Figs. 2 -- 4	52215
Figs. 2	52215
4	52223
there	52239
differences in how OEC type and transplantation approach affect axonal sprouting	52252
differences	52252
OEC type and transplantation approach	52271
OEC type	52271
transplantation approach	52284
Sprouting of NF + axons within the lesion site	52334
Sprouting	52334
NF + axons within the lesion site	52347
NF + axons	52347
the lesion site	52364
greatest in rats that received rostrocaudal LP OEC transplants , with little axon density decrease across the lesion site -LRB- Fig. 5 -RRB-	52384
greatest	52384
rats that received rostrocaudal LP OEC transplants , with little axon density decrease across the lesion site -LRB- Fig. 5 -RRB-	52396
rats	52396
rostrocaudal LP OEC transplants	52415
little axon density decrease	52453
the lesion site	52489
Fig. 5	52506
contrast	52518
direct transplantation of LP OECs	52537
direct transplantation	52537
LP OECs	52563
axons	52596
the lesion boundaries	52609
fewer axons	52632
the lesion/host interface	52667
This effect	52694
a result of both trophic/tropic actions of OECs and changes to the permissiveness of the glial scar/lesion site	52715
a result	52715
both trophic/tropic actions of OECs and changes to the permissiveness of the glial scar/lesion site	52727
both trophic/tropic actions	52727
OECs and changes to the permissiveness of the glial scar/lesion site	52758
OECs and changes	52758
the permissiveness of the glial scar/lesion site	52778
the permissiveness	52778
the glial scar/lesion site	52800
rostrocaudal transplantation	52836
GFAP reactivity and cavity formation -LRB- Fig. 3 -RRB-	52880
GFAP reactivity and cavity formation	52880
Fig. 3	52918
permissiveness	52938
tropic actions	52966
rostrocaudal	53001
direct , LP OEC transplantation	53032
direct	53032
LP OEC transplantation	53040
only the location of the cell transplant	53076
only the location	53076
the cell transplant	53097
differences in NF + growth	53138
differences	53138
NF + growth	53153
NF	53153
growth	53157
evidence from LP OECs	53180
evidence	53180
LP OECs	53194
one	53203
-LRB- 1 -RRB- greater NF + axons within the lesion site in rats transplanted rostrocaudally than directly with OB OECs and -LRB- 2 -RRB- the same amount of NF + growth within the lesion site in rostrocaudal LP - and OB-treated rats	53220
-LRB- 1 -RRB- greater NF + axons within the lesion site in rats transplanted rostrocaudally than directly with OB OECs	53220
greater	53224
NF + axons within the lesion	53232
NF + axons	53232
the lesion	53249
site in rats transplanted rostrocaudally than directly with OB OECs	53260
site	53260
rats transplanted rostrocaudally than directly with OB OECs	53268
rats	53268
OB OECs	53320
-LRB- 2 -RRB- the same amount of NF + growth within the lesion site in rostrocaudal LP - and OB-treated rats	53332
-LRB- 2 -RRB- the same amount of NF	53332
the same amount	53336
NF	53355
growth within the lesion site in rostrocaudal LP - and OB-treated rats	53359
growth	53359
the lesion site in rostrocaudal LP - and OB-treated rats	53373
the lesion site	53373
rostrocaudal LP - and OB-treated rats	53392
A comparison of only rostrocaudally transplanted LP and OB OEC rats	53430
A comparison	53430
only rostrocaudally transplanted LP and OB OEC rats	53446
only rostrocaudally transplanted LP	53446
OB OEC rats	53486
significantly greater NF + axons	53509
NF + axons	53531
the lesion in LP-treated rats -LRB- Fig. 5 -RRB-	53560
the lesion	53560
LP-treated rats -LRB- Fig. 5 -RRB-	53574
LP-treated rats	53574
Fig. 5	53591
This	53600
LP and OB OECs	53619
different neurotrophic factors	53648
them	53694
different levels	53702
The significant increase in autotomy in LP OEC versus OB OEC transplant groups	53720
The significant increase	53720
autotomy in LP OEC versus OB OEC transplant groups	53748
autotomy	53748
LP OEC versus OB OEC transplant groups	53760
LP OEC	53760
OB OEC transplant groups	53774
potential functional differences between these two cell types	53819
potential functional differences	53819
these two cell types	53860
the mechanisms of autotomy	53891
the mechanisms	53891
autotomy	53909
autotomy	53938
denervation or situations	53963
sensory modalities	53998
our model	54040
it	54063
OEC transplantation	54079
the sensory system	54119
differential growth of different axonal populations	54154
differential growth	54154
different axonal populations	54177
local circuitry	54236
These possibilities	54253
a higher degree of plasticity/remodeling	54284
a higher degree	54284
plasticity/remodeling	54303
LP versus OB OECs , which could result in undesired effects	54343
LP versus OB OECs	54343
undesired effects	54384
comparison	54406
recent work with transplanted embryonic stem cells into SCI	54418
recent work	54418
transplanted embryonic stem cells into SCI	54435
transplanted embryonic stem cells	54435
SCI	54474
the development of allodynia	54491
the development	54491
allodynia	54510
addition	54523
increased motor function , a feature not tested in mostOECtransplantation studies -LRB- Hofstetter et al. , 2005 -RRB-	54535
increased motor function	54535
a feature	54561
mostOECtransplantation studies -LRB- Hofstetter et al. , 2005 -RRB-	54585
mostOECtransplantation studies	54585
Hofstetter	54617
et al. , 2005	54628
et al.	54628
2005	54636
The differential sprouting of some axonal populations	54643
The differential	54643
some axonal populations	54673
LP and OB OECs	54718
different neurotrophic factors	54741
recovery -LRB- Fig. 8 -RRB-	54810
recovery	54810
Fig. 8	54820
subP + axons	54829
subP	54829
axons	54835
OB	54872
LP-treated rats -LRB- Fig. 8 -RRB-	54881
LP-treated rats	54881
Fig. 8	54898
the most robust difference in sprouting	54916
the most robust difference	54916
the growth of TH + neurons , whose growth was highly promoted by LP OEC transplantation -LRB- Fig. 8 -RRB-	54960
the growth	54960
TH + neurons , whose growth was highly promoted by LP OEC transplantation -LRB- Fig. 8 -RRB-	54974
TH + neurons	54974
growth	54993
LP OEC transplantation -LRB- Fig. 8 -RRB-	55023
LP OEC transplantation	55023
Fig. 8	55047
Differences in the abilities of LP and OB OECs to promote axon elongation	55056
Differences	55056
the abilities of LP and OB OECs to promote axon elongation	55071
the abilities	55071
LP and OB OECs	55088
axon elongation	55114
accord with their roles in the olfactory neuraxis	55137
accord	55137
their roles in the olfactory neuraxis	55149
their roles	55149
the olfactory neuraxis	55164
OB OECs	55210
NGF , BDNF , glial cell line-derived neurotrophic factor , artemin , and CNTF in vivo and in vitro -LRB- Woodhall et al. , 2001 ; Lipson et al. , 2003 -RRB- ,	55226
NGF	55226
BDNF , glial cell line-derived neurotrophic factor , artemin , and CNTF in vivo and in vitro -LRB- Woodhall et al. , 2001 ; Lipson et al. , 2003 -RRB-	55231
BDNF , glial cell line-derived neurotrophic factor , artemin , and CNTF in vivo and in vitro	55231
BDNF	55231
glial cell line-derived neurotrophic factor , artemin , and CNTF in vivo	55237
glial cell line-derived neurotrophic factor , artemin ,	55237
glial cell	55237
line-derived neurotrophic factor , artemin ,	55248
line-derived neurotrophic factor	55248
artemin	55282
CNTF in vivo	55295
CNTF	55295
vivo	55303
Woodhall	55322
et al. , 2001 ; Lipson et al. , 2003	55331
et al.	55331
2001 ; Lipson et al.	55339
2001	55339
Lipson et al.	55345
Lipson	55345
et al.	55352
2003	55360
their ability to promote outgrowth of peripheral ganglia and CNS explants as well as to promote sprouting within the spinal cord via secreted	55367
outgrowth of peripheral ganglia and CNS explants	55392
outgrowth	55392
peripheral ganglia and CNS explants	55405
the spinal cord via secreted	55480
the spinal cord	55480
factors	55509
their ability	55544
direct cell	55571
cell contact	55584
Sonigra et al. , 1999 ; Lipson et al. , 2003 ; Chuah et al. , 2004	55609
Sonigra	55609
et al. , 1999 ; Lipson et al. , 2003 ; Chuah et al. , 2004	55617
et al. , 1999	55617
et al.	55617
1999	55625
Lipson et al. , 2003	55631
Lipson	55631
et al. , 2003	55638
et al.	55638
2003	55646
Chuah et al. , 2004	55652
Chuah	55652
et al. , 2004	55658
et al.	55658
2004	55666
we	55679
the first data directly comparing LP and OB OEC transplantation in a single SCI model	55690
the first data	55690
LP and OB OEC transplantation in a single SCI model	55724
LP and OB OEC transplantation	55724
a single SCI model	55757
there	55790
fundamental differences in intrinsic OEC properties that are retained after they are transplanted into lesioned spinal cord	55800
fundamental differences	55800
intrinsic OEC properties	55827
they	55876
lesioned spinal cord	55903
These differences	55925
-LRB- 1 -RRB- the ability to migrate and create a permissive regeneration-promoting environment at the lesion site and -LRB- 2 -RRB- differential outgrowth-promoting characteristics of LP and OB OECs	55953
-LRB- 1 -RRB- the ability to migrate and create a permissive regeneration-promoting environment at the lesion site	55953
the ability	55957
a permissive regeneration-promoting environment	55991
the lesion site	56042
-LRB- 2 -RRB- differential outgrowth-promoting characteristics of LP and OB OECs	56062
differential outgrowth-promoting characteristics	56066
LP and OB OECs	56118
the maximal benefit to most regeneration parameters	56143
the maximal benefit	56143
most regeneration parameters	56166
most	56166
regeneration parameters	56171
rostrocaudal LP OEC transplantation	56213
this	56250
autotomy	56279
This	56289
the vigorous sprouting associated with rostrocaudal LP OEC transplantation	56308
the vigorous	56308
rostrocaudal LP OEC transplantation	56347
appropriate connections	56410
nearby uninjured tracts	56470
rostrocaudal LP OEC transplantation	56528
the greatest opportunity	56573
regeneration	56609
local circuitry	56635
SCI	56657
LP OECs , combined with directed axon guidance stimulation ,	56678
LP OECs	56678
directed axon guidance stimulation	56701
additional development	56747
a means to restore motor and sensory function after spinal cord lesion	56773
motor and sensory function	56792
spinal cord lesion	56825
